280 results on '"M. Ferrer"'
Search Results
2. Papovavirus Clínica, diagnóstico clínico y tratamiento
- Author
-
M. Ferrer Gispert
- Subjects
Medicine - Abstract
Cada vez está cobrando mayor valor la etiología vírica de la CIN (neoplasia intrae- .pitelial cervical), concretamente el papel oncogénico dei papovavirus. Entre los DNA vírus se ha atribuído papel oncogénico ai herpes simple virus (HSV-2), papovavirus (HPV). citomegalovirus (CMV) y es cuestionable la acción de los retrovirus. EI concepto de condiloma ha cambiado totalmente en los últimos doce anos. En 1975 la única infección por papovavirus humano (HPV) dei tracto genital que se conocía era el condiloma acuminado, afectando principalmente la vulva y mucho más raramente el cérvix.
- Published
- 1990
3. Outpatient treatment in acute uncomplicated diverticulitis
- Author
-
Á Reina Duarte, M García Redondo, Z Gómez Carmona, I Blesa Sierra, M Ferrer Márquez, and P Moya Forcén
- Subjects
medicine.medical_specialty ,business.industry ,medicine ,General Medicine ,business ,Surgery ,Uncomplicated diverticulitis - Abstract
Resumen La mayoría de los casos de inflamación diverticular son leves y solo requieren tratamiento médico con dieta líquida y antibióticos. Hasta hace poco, este tratamiento requería ingreso hospitalario con los consiguientes costes. El tratamiento ambulatorio de estos pacientes con diverticulitis no complicada ha demostrado ser eficaz y seguro. El objetivo de esta revisión es describir el tratamiento ambulatorio con antibiótico oral y los resultados publicados.
- Published
- 2021
4. Incidence of colorectal cancer after acute diverticulitis
- Author
-
M Ferrer Márquez, P Moya Forcén, I Teruel Lillo, FA Rubio Gil, J Jorge Cerrudo, Z Gómez Carmona, and Á Reina Duarte
- Subjects
medicine.medical_specialty ,Acute diverticulitis ,Colorectal cancer ,business.industry ,Incidence (epidemiology) ,Internal medicine ,medicine ,General Medicine ,medicine.disease ,business ,Gastroenterology - Abstract
Resumen Tras un episodio de diverticulitis aguda la realización de una colonoscopia de rutina ha sido defendida en las guías de práctica clínica de numerosas sociedades. Sin embargo, en los últimos años en contraposición a esto, numerosos estudios han intentado demostrar que no existe esta necesidad en todos los casos. ya que la incidencia de adenomas de alto grado (AA) y cáncer colorrectal (CCR) en la diverticulitis aguda no complicada es bajo y prácticamente similar al que encontramos en la población sometida a programas de screening, mientras que sería necesaria en pacientes con diverticulitis aguda complicada.
- Published
- 2021
5. Current status of the laparoscopic approach, lavage and draining in complicated acute diverticular disease
- Author
-
I Blesa Sierra, M Ferrer Márquez, Á Reina Duarte, J Jorge Cerrudo, C Gras Fernández, and FA Rubio Gil
- Subjects
medicine.medical_specialty ,business.industry ,General surgery ,medicine ,Diverticular disease ,General Medicine ,Current (fluid) ,business - Abstract
Resumen La enfermedad diverticular es uno de los trastornos gastrointestinales más frecuentes en el mundo occidental, y su presentación aguda se desarrollará en un 10-25% de los pacientes diagnosticados. Se presenta, a continuación, una revisión de conjunto sobre el tratamiento laparoscópico actual de la diverticulitis aguda, así como del lavado y drenaje laparoscópico.
- Published
- 2021
6. Concomitant and decoupled effects of cigarette smoke and SCAL1 upregulation on oncogenic phenotypes and ROS detoxification in lung adenocarcinoma cells
- Author
-
Jose Lorenzo M Ferrer, Reynaldo L. Garcia, and Carmela Rieline V Cruz
- Subjects
Carcinogenesis ,Molecular biology ,Science ,Pathogenesis ,Biology ,Article ,Downregulation and upregulation ,medicine ,Humans ,Lung cancer ,Carcinogen ,Cancer ,A549 cell ,Gene knockdown ,Multidisciplinary ,Molecular medicine ,medicine.disease ,Long non-coding RNA ,Up-Regulation ,Oncology ,A549 Cells ,Alveolar Epithelial Cells ,Cancer research ,Adenocarcinoma ,Medicine ,RNA, Long Noncoding ,Tobacco Smoke Pollution ,Reactive Oxygen Species - Abstract
Lung cancer is the leading cause of cancer deaths worldwide, with smoking as its primary predisposing factor. Although carcinogens in cigarettes are known to cause oncogenic DNA alterations, analyses of patient cohorts revealed heterogeneous genetic aberrations with no clear driver mutations. The contribution of noncoding RNAs (ncRNAs) in the pathogenesis of lung cancer has since been demonstrated. Their dysregulation has been linked to cancer initiation and progression. A novel long noncoding RNA (lncRNA) called smoke and cancer-associated lncRNA 1 (SCAL1) was recently found upregulated in smoke-exposed adenocarcinomic alveolar epithelial cells. The present study characterized the phenotypic consequences of SCAL1 overexpression and knockdown using A549 cells as model system, with or without prior exposure to cigarette smoke extract (CSE). Increase in SCAL1 levels either by CSE treatment or SCAL1 overexpression led to increased cell migration, extensive cytoskeletal remodeling, and resistance to apoptosis. Further, SCAL1 levels were negatively correlated with intracellular levels of reactive oxygen species (ROS). In contrast, SCAL1 knockdown showed converse results for these assays. These results confirm the oncogenic function of SCAL1 and its role as a CSE-activated lncRNA that mediates ROS detoxification in A549 cells, thereby allowing them to develop resistance to and survive smoke-induced toxicity.
- Published
- 2021
7. Female gender and knowing a person positive for COVID-19 significantly increases fear levels in the Cuban population
- Author
-
Elizabeth Jiménez-Puig, Dunia M Ferrer-Lozano, Zoylen Fernández-Fleites, Annia E Vizcaino Escobar, Yunier Broche-Pérez, Lesnay Martínez-Rodríguez, Boris C. Rodríguez-Martín, Evelyn Fernández-Castillo, and Martín-González R
- Subjects
2019-20 coronavirus outbreak ,education.field_of_study ,Scale (ratio) ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Health Policy ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Population ,Public Health, Environmental and Occupational Health ,Sample (statistics) ,Psychiatry and Mental health ,Medicine ,Psychology ,business ,education ,Demography - Abstract
The objective of this study was to explore the relationship between sociodemographic factors and fear of COVID-19 in a Cuban population. A web-based study with a cross-sectional design was conducted. The sample comprised 1145 participants. To explore fear, the Fear of COVID-19 Scale was used. Our results suggest that women were more likely to experience medium to high levels fear compared to men. Additionally, knowing a person positive to COVID-19 significantly increases fear levels in Cuban participants.
- Published
- 2021
8. Long-term outcomes of patients following hospitalization for coronavirus disease 2019: a prospective observational study
- Author
-
M. Vaqué, G. Rodríguez-Froxán, C. Ferré, L. Ventura, C. Vericat, A. Odriozola, J.R. Pérez-Mas, J. Garrillo, G. Martí, J.M. Soler, A. Vila, A. Coco, A. Musolas, A. Martínez-Trillos, M.J. Elizari, Mercedes Clemente, K. Pizurno, L. Iglesias, Teresa Sagués, N. Espaulella, N. Baeza, E. García, Ana Ayestarán, Jaume LLaberia, N. Stasi, Miquel Ariño, N. Alguersuari, A. Santamaría, I. Escape, Júlia Pareja, A. Méndez, Beatriz Candás-Estébanez, S. Pons, Yolanda Meije, Nuria Fernández-Hidalgo, F. Franco, M.A. Palos, J. Mercé, S. Mechó, L. Martínez-Fijo, J. Cabello, J. Jimeno, J. Bugés, Alba Ribera, J. Cantos, B. Mendiola, Irene Cantero, J. Morillas, J. Galí, D. Redó, M. Ponce, C. Guzmán, J. Lima, J. Martínez-Montauti, E. Parra, Alejandra Duarte-Borges, L. Invernón, J. Palau, M. Campillo, M. León, Xavier Sanz, M. Montané, A. Arderiu, X. Demestre, V. Pagès, I. Coll, D. Coroleu, J. Martínez-Agea, J. Costa, C. Sitges, Ruth González-Pérez, S. Martínez, A. Torrens, P. Díez-Cascón, Roser Cid, N. Rodón, Lucía Ortega, E. Castellarnau, F. Miranda, J. Fabregat, and M. Ferrer
- Subjects
Male ,0301 basic medicine ,Microbiology (medical) ,Pediatrics ,medicine.medical_specialty ,Multivariate analysis ,Coronavirus disease 2019 (COVID-19) ,030106 microbiology ,Tertiary Care Centers ,Sequelae ,03 medical and health sciences ,0302 clinical medicine ,Outpatient facility ,Long term outcomes ,Humans ,Medicine ,Prospective Studies ,Survivors ,030212 general & internal medicine ,General hospital ,Prospective cohort study ,Lung ,Aged ,Aged, 80 and over ,SARS-CoV-2 ,business.industry ,Follow-up ,PaO2/FiO2 ,COVID-19 ,Aftermath ,General Medicine ,Middle Aged ,respiratory system ,COVID-19 Drug Treatment ,respiratory tract diseases ,Hospitalization ,Oxygen ,Logistic Models ,Infectious Diseases ,Spain ,Radiological weapon ,Multivariate Analysis ,Female ,Original Article ,Observational study ,business ,Follow-Up Studies ,circulatory and respiratory physiology - Abstract
OBJECTIVES Few data regarding follow-up of patients after COVID-19 discharge are available. We aim to describe the long-term outcomes of survivors of hospitalization for COVID-19 followed up first at an outpatient facility and subsequently by telephone. METHODS Observational prospective study conducted at a tertiary general hospital. Clinical and radiological progression was assessed and data recorded on a standardized reporting form. Patients were divided into three groups according to PaO2/FiO2 at hospitalization: PaO2/FiO2 > 300, PaO2/FiO2 300-200 and PaO2/FiO2 < 200. A logistic multivariate regression model was performed to identify factors associated with persistence of symptoms. RESULTS Facility follow-up: 302 patients were enrolled. Median follow-up was 45 days after discharge; 78% (228/294) of patients had COVID-19-related symptoms (53% asthenia, 56% respiratory symptoms) and 40% (122/302) had residual pulmonary radiographic lesions. PaO2/FiO2 300 was associated with resolution of chest radiographic lesions; OR = 0.56 (0.42 to 0.74), (p, Graphical abstract Image 1
- Published
- 2021
9. Sumario de las recomendaciones y puntos clave del Consenso de las Sociedades Científicas Españolas (SEPAR, SEMICYUC, SEMES; SECIP, SENeo, SEDAR, SENP) para la utilización de la ventilación no invasiva y terapia de alto flujo con cánulas nasales en el paciente adulto, pediátrico y neonatal con insuficiencia respiratoria aguda grave
- Author
-
Manel Luján, E. Farrero Muñoz, Arantxa Mas, G. Hernández, J. Parrilla Parrilla, Carlos Ferrando Ortola, Rafael Uña, A. Concheiro Guisán, Mónica González, Sarah Heili-Frades, I. Gutiérrez Ibarluzea, J.M. Carratalá Perales, A. Romero Berrocal, J. Moreno Hernando, M. Ferrer Monreal, Mirella Gaboli, J. García Fernández, Joaquín Escámez, C. Egea Santaolalla, Oscar Peñuelas, J.F. Masa Jiménez, Alberto García-Salido, G. Rialp Cervera, M.A. Sanchez Quiroga, César Cinesi Gómez, and A.M. Sánchez Torres
- Subjects
03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,business.industry ,Medicine ,030208 emergency & critical care medicine ,Critical Care and Intensive Care Medicine ,business ,Humanities - Abstract
Resumen El soporte respiratorio no invasivo (SRNI) comprende 2 modalidades de tratamiento, la ventilacion meca-nica no invasiva (VMNI) y la terapia de alto flujo con canulas nasales (TAFCN) que se aplican en pacientes adultos, pediatricos y neonatales con insuficiencia respiratoria aguda (IRA). Sin embargo, el grado de acuerdo entre las distintas especialidades sobre el beneficio de estas tecnicas en diferentes escenarios clinicos es controvertido. El objetivo del presente consenso fue elaborar una serie de recomendaciones de buena practica clinica para la aplicacion de soporte no invasivo en pacientes con IRA, avaladas por todas las sociedades cientificas involucradas en el manejo del paciente adulto y pediatrico/neonatal con IRA. Para ello se contacto con las diferentes sociedades implicadas, quienes designaron a su vez a un grupo de 26 profesionales con suficiente experiencia en su aplicacion. Se realizaron 3 reuniones presenciales para consensuar las recomendaciones (hasta un total de 71) fundamentadas en la revision de la literatura y en la actualizacion de la evidencia disponible en relacion con 3 categorias: indicaciones, monitorizacion yseguimiento del SRNI. Finalmente, se procedio a votacion telematica de cada una de las recomendaciones, por parte de los expertos de cada sociedad cientifica implicada. Para la clasificacion del grado de acuerdo se opto por un sistema analogico de clasificacion facil e intuitivo de usar, y que expresara con claridad si el procedimiento relacionado con el SRNI debia hacerse, podia hacerse o no debia hacerse.
- Published
- 2021
10. The impact of a cardiopulmonary resuscitation video on reducing surrogates' anxiety: A pilot randomized controlled trial
- Author
-
Matthew W. Weber, Jeanette Graf, Zhuping Garacci, Anjishnu Banerjee, Meghan Nothem, Kumar Shah, Tirsa M. Ferrer Marrero, Jennifer Kryworuchko, Jayshil J. Patel, Besma Jaber, Patrick Kennedy, Shannon Broaddrick, Mark Barash, and Stephanie Zellner Jones
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Decision Making ,Pilot Projects ,Anxiety ,Code status ,Critical Care and Intensive Care Medicine ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Severity of illness ,medicine ,Humans ,Prospective Studies ,Cardiopulmonary resuscitation ,business.industry ,Significant difference ,030208 emergency & critical care medicine ,Cardiopulmonary Resuscitation ,Test (assessment) ,Intensive Care Units ,030228 respiratory system ,Physical therapy ,SOFA score ,medicine.symptom ,business - Abstract
Purpose To test the primary hypothesis that a CPR video will reduce ICU patients' surrogates' anxiety when deciding code status, as measured by the Hamilton Anxiety Rating (HAM-A) Scale, as compared to the no video group. Materials and methods This is a prospective randomized control trial. Twenty-seven ICU patients' surrogates were enrolled in the study after receiving an ICU team-led code status discussion. After the enrollment, twelve surrogates were randomized to the video group and fifteen to the no video group. The primary outcome of anxiety was quantified using the HAM-A Scale. Demographic information, clinical data, and patients' provenance information (Home vs. Not Home) were collected. The patients' severity of illness was calculated using the Sequential Organ Failure Assessment (SOFA) Score. Results The HAM-A score in the video group was 5.65 points lower than in the no video group ([β = −5.65, 95% CI −11.12 −0.18] P = 0.04). The statistically significant difference was maintained when adjusting for patients' SOFA Score and patients' provenance (P = 0.03). Conclusion CPR video used to supplement ICU team-led code status discussions reduced surrogates' anxiety, as compared to no video. Trial Registration: ClinicalTrials.gov Identifier NCT03630965 .
- Published
- 2021
11. A unique subset of glycolytic tumor propagating cells drives squamous cell carcinoma
- Author
-
Thomas J. LaSalle, Carlos Sebastian, Begoña Gimenez-Cassina Lopez, Itay Tirosh, Jee-Eun Choi, Giórgia Gobbi da Silveira, Leif W. Ellisen, Walid M. Abdelmoula, Anna L.K. Gonye, Nathalie Y. R. Agar, Raul Mostoslavsky, Kenneth N. Ross, Gregory R. Wojtkiewicz, Christina M. Ferrer, Srinivas Vinod Saladi, Ruben Boon, Ruslan I. Sadreyev, Salvador Aznar Benitah, Murat Cetinbas, Moshe Sade-Feldman, Gloria Pascual, Caroline A. Lewis, Nir Hacohen, and Michael S. Regan
- Subjects
Endocrinology, Diabetes and Metabolism ,Biology ,Pentose phosphate pathway ,Article ,Antioxidants ,Head cancer ,Pentose Phosphate Pathway ,Mice ,Single-cell analysis ,Physiology (medical) ,Internal Medicine ,medicine ,Animals ,Humans ,Sirtuins ,Glycolysis ,RNA, Neoplasm ,Càncer de cap ,Cell proliferation ,Mice, Knockout ,Proliferació cel·lular ,Squamous Cell Carcinoma of Head and Neck ,Cell Biology ,Neck cancer ,medicine.disease ,Warburg effect ,Head and neck squamous-cell carcinoma ,Glutathione ,Xenograft Model Antitumor Assays ,Càncer de coll ,Mice, Inbred C57BL ,Anaerobic glycolysis ,Head and Neck Neoplasms ,Sirtuin ,biology.protein ,Cancer research ,Disease Progression ,Neoplastic Stem Cells ,Histone deacetylase ,Single-Cell Analysis - Abstract
Head and Neck Squamous Cell Carcinoma (HNSCC) remains among the most aggressive human cancers. Tumor progression and aggressiveness in SCC are largely driven by Tumor Propagating Cells (TPCs). Aerobic glycolysis, also known as the Warburg Effect, represents a characteristic of many cancers, yet whether this adaptation is functionally important in SCC, and at which stage, remains poorly understood. Here, we show that the NAD+-dependent histone deacetylase Sirtuin 6 (SIRT6) is a robust tumor suppressor in SCC, acting as a modulator of glycolysis in these tumors. Remarkably, rather than a late adaptation, we find enhanced glycolysis specifically in TPCs. More importantly, using single cell RNA sequencing of TPCs, we identify a subset of TPCs with higher glycolysis and enhanced pentose phosphate pathway and glutathione metabolism, characteristics that are strongly associated with a better antioxidant response. Altogether, our studies uncover enhanced glycolysis as a main driver in SCC, and, more importantly, identify a subset of TPCs as the cell-of-origin for the Warburg effect, defining metabolism as a key feature of intra-tumor heterogeneity.
- Published
- 2021
12. Adaptation of the Cuban version of the Coronavirus Anxiety Scale
- Author
-
Yunier Broche-Pérez, Lesnay Martínez-Rodríguez, Martín-González R, Elizabeth Jiménez-Puig, Annia Esther Vizcaíno-Escobar, Dunia M Ferrer-Lozano, Evelyn Fernández-Castillo, and Zoylen Fernández-Fleites
- Subjects
education.field_of_study ,Psychometrics ,Concurrent validity ,Population ,Single factor ,COVID-19 ,Reproducibility of Results ,Anxiety ,medicine.disease_cause ,Anxiety Disorders ,humanities ,Confirmatory factor analysis ,Clinical Psychology ,Arts and Humanities (miscellaneous) ,Internal consistency ,Developmental and Educational Psychology ,medicine ,Humans ,medicine.symptom ,Psychology ,education ,Anxiety scale ,Coronavirus ,Clinical psychology - Abstract
This study explores the psychometric properties of the Cuban version of Coronavirus Anxiety Scale (CAS). The sample comprised 376 Cuban participants. Concurrent validity and reliability were examined. A confirmatory factor analysis was performed. The CAS showed excellent psychometric characteristics. The internal consistency was very good (α = 0.88). There was a positive correlation between the CAS and the FCV-19S and an inverse association between anxiety and self-perceived quality of health. The results confirmed the presence of a single factor. The CAS is a valid and reliable instrument to explore the experience of anxiety in the Cuban population.
- Published
- 2020
13. Revisión sistemática del tratamiento de la espasticidad en el adulto con daño cerebral adquirido
- Author
-
M. Cerezo Durá, D. Goiri Noguera, M. Ferrer Pastor, A. Sogues Colom, V. Iñigo Huarte, and J. Diaz
- Subjects
Motor disorder ,030506 rehabilitation ,Pediatrics ,medicine.medical_specialty ,Traumatic brain injury ,business.industry ,Rehabilitation ,Physical Therapy, Sports Therapy and Rehabilitation ,Brain damage ,medicine.disease ,Botulinum toxin ,Jadad scale ,03 medical and health sciences ,Muscle tone ,0302 clinical medicine ,medicine.anatomical_structure ,medicine ,Spasticity ,medicine.symptom ,0305 other medical science ,business ,Stroke ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Spasticity is a motor disorder characterised by an increase in muscle tone that appears as a consequence of a central nervous system disorder, leading to deficit and disability and impairing quality of life. In acquired adult brain damage, spasticity is a severe and frequent problem, appearing in 20-30% of patients with stroke and in 13-20% of patients with moderate-severe traumatic brain injury. The main objective of this study was to perform a systematic review of the treatments used in spasticity in adult patients with acquired brain damage secondary to stroke and head trauma. A systematic search of randomised controlled trials, published between January 1, 2013 and June 30, 2017 in English and Spanish, was carried out in the PubMed, Cochrane plus Library and Ovid databases. We finally selected 17 studies, with methodological quality that was at least acceptable according to the Jadad scale. The most frequently investigated treatments are botulinum toxin, especially serotype A, together with rehabilitative measures. Clinical scales are the most frequently used to assess spasticity.
- Published
- 2020
14. WITHDRAWN: Daily Clinical Practice in the Management of Chronic Urticaria in Spain: Results of the UCREX Study
- Author
-
P. Terradas-Montana, I. Jáuregui Presa, F.J. Ortiz de Frutos, M. Vidal-Jorge, J.F. Silvestre Salvador, J. Sastre Dominguez, A. Giménez-Arnau, A. Valero Santiago, M. Ferrer Puga, J. Miquel-Miquel, J. Bartra Tomàs, and Moises Labrador-Horrillo
- Subjects
medicine.medical_specialty ,Histology ,business.industry ,Dermatology ,Disease ,Hospital Anxiety and Depression Scale ,Pathology and Forensic Medicine ,Clinical Practice ,Internal medicine ,Health care ,medicine ,Anxiety ,Disease management (health) ,medicine.symptom ,business ,Chronic urticaria ,Depression (differential diagnoses) - Abstract
Background Chronic Urticaria (CU) is a debilitating disease whose treatment is mainly symptomatic. UCREX study aimed to identify CU patients’ profile, disease management and quality-of-life (QoL) in daily clinical practice in Spain. Methods Observational, 12-months prospective, multicenter study, included de novo or established CU patients attending to dermatology/allergy consultations in 39 Spanish hospitals. Main variables: Urticaria Activity Score (UAS), UAS over 7 days (UAS7). Secondary variables: CU-QoL Questionnaire (CU-Q2oL), EuroQol-5 dimensions (EQ-5D), Medical Outcomes Study Sleep (MOS-Sleep) scale, Hospital Anxiety and Depression Scale (HADS). Results 361 patients included. Of them, 176 (48.8%) considered for the main objective analysis. Mean age (SD) of 46.6 (14.2) years and 71.8% women. The year prior to inclusion, most patients (57.1%) were treated with non-sedating H1-antihistamines (NS-H1AH). At baseline, mean (SD) 3.6 (6.8) visits were registered to primary care. Mean (SD) UAS7 at baseline was 14.3 (11.0) and CU-Q2oL 24.1 (17.0) which tended to improve by 8.6 (9.7) and 13.9 (15.0), respectively, at 12-months. MOS-Sleep and EQ-5D remained steady during the study, except pain/discomfort and anxiety/depression which went from 58.7% and 49.6% to 29.6% and 26.9%, respectively. At baseline, HADS showed a mean (SD) anxiety of 8.7 (4.5) and depression 5.1 (4.4), decreasing to 7.0 (4.3) and 4.7 (4.3), respectively, at 12-months. Conclusions Although most CU patients are treated with NS-H1AH, disease activity is still important, negatively affecting patients’ QoL, work activity and healthcare resources use. An appropriate disease management could be the basis for symptoms control, QoL improvement and resources optimization.
- Published
- 2021
15. Follow-Up Cultures in Ventilator-Associated Pneumonia
- Author
-
N. Stefano, G. Albert, Adrian Ceccato, M. Ignacio, M. Ferrer Monreal, Otavio T. Ranzani, A. Torres, Cristina Dominedò, P. Di Giannatale, G. De Pascale, Enric Barbeta, Catia Cillóniz, and Massimo Antonelli
- Subjects
medicine.medical_specialty ,business.industry ,Ventilator-associated pneumonia ,medicine ,medicine.disease ,business ,Intensive care medicine - Published
- 2021
16. Advantages of the medial approach in the dissection of the splenic angle of the colon
- Author
-
F Rubio, P Moya Forcén, M Ferrer, and A Reina
- Subjects
business.industry ,Medial approach ,Medicine ,General Medicine ,Dissection (medical) ,Anatomy ,business ,medicine.disease - Abstract
Resumen La movilización del ángulo esplénico del colon es considerada una maniobra compleja y de las más desafiantes en la cirugía colorrectal con vía laparoscópica. A pesar de que existen distintas opciones quirúrgicas para llevarla a cabo, el abordaje de medial a lateral debe ser la técnica de elección. A continuación, se presenta la técnica quirúrgica y la ventajas de este abordaje.
- Published
- 2019
17. Abstract P5-15-09: Impact of oncotype dx genetic signature used in early breast cancer. Clinical and economic analisys of a 110 patient cohort treated in the Catalan Oncologic Institute (ICO), Spain
- Author
-
Beatriz Cirauqui, Catalina Falo, Sabela Recalde, Gemma Viñas, M Ferrer, Argentina Fernández, Mireia Margeli, J Dorcas, Miguel Gil-Gil, R Villanueva, A. Vethencourt, Anna Petit, Teresa Soler, Silvia Vazquez, Vanesa Quiroga, Margarita Romeo, S. Del Barco, Agostina Stradella, and X. Perez-Martin
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Cancer ,computer.file_format ,medicine.disease ,Logistic regression ,Genetic signature ,Breast cancer ,MammaPrint ,Internal medicine ,Cohort ,medicine ,ICO ,Oncotype DX ,business ,computer - Abstract
Introduction Benefit from adjuvant chemotherapy (CT) is doubtful in a high percentage of patients with early breast cancer. The 21-gene recurrence-score (RS) assay (Oncotype DX, Genomic Health) is one gene-expression assay that provide prognostic and predictive information in hormone-receptor (RH) positive breast cancer. The results of the TAILORx study have confirmed that the majority of patients with tumors RH + and HER2 negative can avoid CT without increasing their risk of relapse. From 2012 to 2015 we used Mammaprint (MMP), in our institution and 60% of cases could avoided CT (communicated in SABCS 2015). Since 2017 we use RS for this purpose. Primary Objective To analyze the impact of using RS to change the indication of adjuvant CT. Secondary Objectives To analyze the association between different clinical pathological factors and the RS value, and calculate the difference between the cost of all RS test and the cost in direct expense of the treatment with CT of all patients who could avoid it thanks to the RS Material and methods We analyzed all RS test performed in the three ICO centers during 2017. We sent 112 tumor samples; in 2 samples adequated RNA for RS was not obtained. We compared the adjuvant treatment initially planned according to institutional treatment protocol with the treatment given after RS. We compared the direct economic costs of CT with the costs of the diagnostic test, and performed a logistic regression analysis of some pathological factors and RS value. Results The RS could be determined in 110 of 112 cases, in which there was indication of adjuvant CT. Only 14 patients received CT (12,72%) with the RS value, so CT was avoided in 96 patients (87,28%). The clinical-pathological characteristics of the series are summarized in the table 1. Of the risk factors analyzed, only grade 3 (p 0.001) and PR 25. No association was found between age, nodal status, tumor diameter, Ki67, Infiltrating Ductal Carcinoma vs neither Infiltrating Lobular Carcinoma nor Lympho-Vascular invasion. The cost of the genetic studies was 180000€ (1636€ each). The cost of each CT schedule (EC x 4 followed by paclitaxel x 12) was 7214€ and the total cost of 96 cases 692590€. Direct costs savings estimated from the reduction in CT treatment were 512590€ Conclusion: Our series shows that RS avoided unnecessary CT in 87% of cases and was more cost-effective than a previous series with MMP. G3 and RP 25. Table 1.Patients characteristics and clinical-pathological details from the analyzed tumorsPatient characteristicsAge, mean (range)53,76 (19 – 75)≥50y72 (65.5%) Citation Format: Ferrer M, Dorcas J, Quiroga V, Margelí M, del Barco S, Stradella A, Petit A, Falo C, Viñas G, Romeo M, Villanueva R, Cirauqui B, Vázquez S, Fernández A, Recalde S, Vethencourt A, Soler T, Pérez-Martín X, Gil-Gil M. Impact of oncotype dx genetic signature used in early breast cancer. Clinical and economic analisys of a 110 patient cohort treated in the Catalan Oncologic Institute (ICO), Spain [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-15-09.
- Published
- 2019
18. Abstract P5-12-14: A pilot study of metabolomics biomarkers in breast cancer tumors treated with neoadjuvant therapy
- Author
-
Lucía Trilla-Fuertes, P. Zamora, R López Vacas, Angelo Gámez-Pozo, Guillermo Prado-Vázquez, J.A. Fresno Vara, M Díaz Almirón, M. Ferrer-Gomez, E. Espinosa, and Andrea Zapater-Moros
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Metabolite ,Cancer ,Omics ,medicine.disease ,chemistry.chemical_compound ,Basal (phylogenetics) ,Breast cancer ,Metabolomics ,chemistry ,Internal medicine ,medicine ,Biomarker (medicine) ,business ,Neoadjuvant therapy - Abstract
Introduction Breast cancer is one of the most prevalent cancers in the world. Traditionally, early breast cancer treatment is based on surgery and, after surgery, hormone treatment or chemotherapy. However, the neoadjuvant treatment is increasingly used. Metabolomics is the most recent “omics” which allows quantify metabolites into blood patient samples. Coupled with computational analyses it could be possible to study differential metabolomics patterns and associate them with neoadjuvant response. Material and methods Blood plasma samples from patients with breast cancer treated with neoadjuvant chemotherapy were used to perform metabolomics experiments. One sample before the treatment (basal) and one sample after the chemotherapy (post-treatment) were analyzed and clinical data regarding response (complete response or partial response) was also collected. Metabolomics experiments were performed using liquid chromatography coupled with mass-spectrometry. Bayesian network and class comparison analyses were used to establish differential metabolic patterns between conditions. Additionally, a response prediction model based on logistic regression was build using metabolomics data from basal samples. Results and discussion A network showing the relationships between metabolites was build. Comparing metabolite measurements between complete response and partial response tumors in basal samples, 19 metabolites showed a differential quantification between both types of responses. Moreover, one of these metabolites is linoleic acid, previously described as a biomarker of complete response in neoadjuvant treatment in breast cancer. Using these 19 differential metabolites, a response predictive model was build. According to this model, it is possible to predict response to neoadjuvant treatment based on the amount of one metabolite, still only identified by its mass and charge. On the other hand, comparing basal and post-treatment samples, the network showed differential metabolomics patterns. These differential metabolites could be used as predictive biomarkers of response. Conclusion This study is a proof of concept that using a new “omics” technique such as metabolomics in blood samples, coupled with computational analyses, it is possible to identify differential metabolomics patterns between complete and partial response or basal and post-treatment samples and design predictive models of response These results could facilitate in the future the implementation of blood-based tests into the clinical routine. Citation Format: Zamora P, Trilla-Fuertes L, Zapater-Moros A, Gámez-Pozo A, Prado-Vázquez G, Ferrer-Gómez M, Díaz- Almirón M, López Vacas R, Espinosa E, Fresno Vara JA. A pilot study of metabolomics biomarkers in breast cancer tumors treated with neoadjuvant therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-12-14.
- Published
- 2019
19. 406.6: Pancreatic Graft Ultrasound Elastography: A Novel Non-invasive Technique in Rejection Assessment
- Author
-
Maria Teresa Rodrigo, Maria Angeles Garcia-Criado, Anna Darnell, Miriam Cuatrecasas, Pedro Ventura Aguiar, Clara Bassaganyas Vancells, Alexandre Soler Perromat, J. M. Ferrer, and Juan Carlos Soler Perromat
- Subjects
Transplantation ,medicine.medical_specialty ,business.industry ,Non invasive ,Ultrasound elastography ,Medicine ,Radiology ,business ,Pancreatic graft - Published
- 2021
20. Anxiety, Health Self-Perception, and Worry About the Resurgence of COVID-19 Predict Fear Reactions Among Genders in the Cuban Population
- Author
-
Yunier Broche-Pérez, Zoylen Fernández-Fleites, Evelyn Fernández-Castillo, Elizabeth Jiménez-Puig, Annia Esther Vizcaíno-Escobar, Dunia M. Ferrer-Lozano, Lesnay Martínez-Rodríguez, and Reinier Martín-González
- Subjects
health self-perception ,Coronavirus disease 2019 (COVID-19) ,fear of COVID-19 ,media_common.quotation_subject ,Population ,Vulnerability ,lcsh:Gynecology and obstetrics ,Global Women's Health ,03 medical and health sciences ,0302 clinical medicine ,Pandemic ,gender ,worry ,medicine ,030212 general & internal medicine ,education ,lcsh:RG1-991 ,General Environmental Science ,Original Research ,media_common ,education.field_of_study ,General Engineering ,lcsh:Women. Feminism ,anxiety ,resurgence ,Mental health ,Scale (social sciences) ,General Earth and Planetary Sciences ,Anxiety ,medicine.symptom ,Worry ,Psychology ,lcsh:HQ1101-2030.7 ,030217 neurology & neurosurgery ,Clinical psychology - Abstract
The resurgence of COVID-19 could deepen the psychological impacts of the pandemic which poses new challenges for mental health professionals. Among the actions that should be prioritized is the monitoring of the groups that have shown greater psychological vulnerability during the first stage of the pandemic. The first aim of our study is to explore the fear reactions to COVID-19 between genders during the second wave of the outbreak in Cuba. Second, establish possible predictors of fear of COVID-19 in relation to gender. Specifically, we will evaluate how anxiety related to COVID-19, health self-perception, and worry about the resurgence of COVID-19 predict fear reactions among women and men in the Cuban population. A cross-sectional online study was designed. The research was conducted between August 16 and October 18, 2020. A total of 373 people completed the online survey. A socio-demographic questionnaire, the Fear of COVID-19 Scale and the Coronavirus Anxiety Scale were used. An independent-samplest-test was conducted to compare the fear, worry, anxiety and self-perceived health scores, between genders. The relationship between those variables and fear of COVID-19, was investigated using Pearson correlation coefficient. Finally, multiple linear regression was used to evaluate the possible associations (predictors) related to fear of COVID-19. In our study, women, compared to men, presented greater fear reactions, greater concern about resurgence of COVID-19 and poorer self-perceived health. Anxiety reactions in our sample showed no differences between genders. In women, anxiety of COVID-19, worry about resurgence of COVID-19, and self-perceived health are associated with fear reactions to COVID-19. In the case of men, the self-perceived health showed no associations with fear reactions. Our results confirm the results of several related investigations during the first wave of the pandemic where women have shown greater psychological vulnerability compared to men. However, we cannot rule out that the real impact of the pandemic on mental health in men is much greater than that described by the studies conducted to date. Additional studies are needed on the psychological impact of COVID-19 on men.
- Published
- 2021
21. No association between vitamin D status and COVID-19 infection in São Paulo, Brazil
- Author
-
Carolina S. Lazari, Maria Izabel Chiamolera, José de Sá, Celso Francisco Hernandes Granato, Pedro de Sá Tavares Russo, Rosa Paula M. Biscolla, José Viana Lima Junior, José Gilberto H. Vieira, Wesley H. Prieto, Cláudia M. Ferrer, and Cynthia Brandão
- Subjects
Adult ,Male ,Coronavirus disease 2019 (COVID-19) ,Endocrinology, Diabetes and Metabolism ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.medical_treatment ,coronavirus ,Physiology ,030209 endocrinology & metabolism ,Diseases of the endocrine glands. Clinical endocrinology ,03 medical and health sciences ,0302 clinical medicine ,Vitamin D and neurology ,medicine ,Humans ,Vitamin D ,Pandemics ,business.industry ,SARS-CoV-2 ,COVID-19 ,RC648-665 ,Vitamin D Deficiency ,Steroid hormone ,030220 oncology & carcinogenesis ,Medicine ,Age distribution ,Female ,business ,Specific population ,Brazil - Abstract
In recent years the immunomodulatory actions of vitamin D, a steroid hormone, have been extensively studied. In 2020, due to the COVID-19 pandemic, the question arose as to 25(OH)D status would be related to susceptibility to SARS-CoV-2 infection, since several studies pointed out a higher prevalence and severity of the disease in populations with low levels of 25(OH)D. Thus, we investigated the 25(OH)D levels in adults “Detected” positive for SARS CoV-2 by RT-PCR (reverse transcriptase polymerase chain reaction) test, and in negative controls, “not Detected”, using the Fleury Group's examination database, in Sao Paulo, Brazil. Of a total of 14.692 people with recent assessments of 25(OH)D and RT-PCR tests for COVID-19, 2.345 were positive and 11.585 were negative for the infection. The groups did not differ in the percentage of men and women, or in the age distribution. There were no differences in the distribution of 25(OH)D between the two groups (p = 0.08); mean 25(OH)D of 28.8 ± 21.4 ng/mL and 29.6 ± 18.1 ng/mL, respectively. In the specific population studied, clinical, environmental, socioeconomic and cultural factors should have greater relevance than 25(OH)D in determining the susceptibility to COVID-19.
- Published
- 2021
22. Paper biosensors for detecting elevated IL-6 levels in blood and respiratory samples from COVID-19 patients
- Author
-
Marcio Borges, María Berman-Riu, Mercedes García-Gasalla, Enrique Barón, Alejandra Alba-Patiño, Giulia Santopolo, J. M. Ferrer, Steven M. Russell, Andreu Vaquer, María Aranda, Roberto de la Rica, Cristina Adrover-Jaume, María del Mar González del Campo, and Antonio Clemente
- Subjects
Coronavirus disease 2019 (COVID-19) ,Paper-based ,02 engineering and technology ,010402 general chemistry ,Systemic inflammation ,01 natural sciences ,Article ,Prognosis biomarker ,Wide dynamic range ,Materials Chemistry ,Medicine ,Electrical and Electronic Engineering ,Interleukin 6 ,Respiratory samples ,Instrumentation ,ComputingMethodologies_COMPUTERGRAPHICS ,Detection limit ,IL-6 ,biology ,SARS-CoV-2 ,business.industry ,Metals and Alloys ,COVID-19 ,021001 nanoscience & nanotechnology ,Condensed Matter Physics ,0104 chemical sciences ,Surfaces, Coatings and Films ,Electronic, Optical and Magnetic Materials ,biology.protein ,Smartphone ,medicine.symptom ,0210 nano-technology ,business ,Biosensor ,Biomedical engineering - Abstract
Graphical abstract, Highlights • Detection of cytokine storm biomarkers with mobile biosensors. • Immunosensors are made solely of cellulose modified with antibody-decorated nanoparticles. • Turnaround time under 10 min. • Detection of biomarkers in respiratory samples allows monitoring local inflammation. • Compatible with decentralized health care schemes., Decentralizing COVID-19 care reduces contagions and affords a better use of hospital resources. We introduce biosensors aimed at detecting severe cases of COVID-19 in decentralized healthcare settings. They consist of a paper immunosensor interfaced with a smartphone. The immunosensors have been designed to generate intense colorimetric signals when the sample contains ultralow concentrations of IL-6, which has been proposed as a prognosis biomarker of COVID-19. This is achieved by combining a paper-based signal amplification mechanism with polymer-filled reservoirs for dispensing antibody-decorated nanoparticles and a bespoken app for color quantification. With this design we achieved a low limit of detection (LOD) of 10−3 pg mL-1 and semi-quantitative measurements in a wide dynamic range between 10−3 and 102 pg mL-1 in PBS. The assay time is under 10 min. The low LOD allowed us to dilute blood samples and detect IL-6 with an LOD of 1.3 pg mL-1 and a dynamic range up to 102 pg mL-1. Following this protocol, we were able to stratify COVID-19 patients according to different blood levels of IL-6. We also report on the detection of IL-6 in respiratory samples (bronchial aspirate, BAS) from COVID-19 patients. The test could be easily adapted to detect other cytokines such as TNF-α and IL-8 by changing the antibodies decorating the nanoparticles accordingly. The ability of detecting cytokines in blood and respiratory samples paves the way for monitoring local inflammation in the lungs as well as systemic inflammation levels in the body.
- Published
- 2021
- Full Text
- View/download PDF
23. Epidemiological and Genetic Characterization of Sapovirus in Patients with Acute Gastroenteritis in Valencia (Spain)
- Author
-
Susana Vila-Vicent, Sibele de Oliveira-Tozetto, Jesús Rodríguez-Díaz, Josep M. Ferrer-Chirivella, Javier Buesa, Cristina Santiso-Bellón, and Noemi Navarro-Lleó
- Subjects
0301 basic medicine ,Diarrhea ,Male ,medicine.medical_specialty ,Genotype ,viruses ,030106 microbiology ,lcsh:QR1-502 ,real-time multiplex PCR ,medicine.disease_cause ,lcsh:Microbiology ,Article ,Astrovirus ,03 medical and health sciences ,genotypes ,Virology ,Rotavirus ,Epidemiology ,medicine ,Prevalence ,Humans ,acute gastroenteritis ,Genotyping ,Phylogeny ,Caliciviridae Infections ,Molecular Epidemiology ,biology ,business.industry ,Coinfection ,Age Factors ,Genetic Variation ,Sapovirus ,biology.organism_classification ,Gastroenteritis ,sapovirus ,030104 developmental biology ,Infectious Diseases ,Spain ,Norovirus ,RNA, Viral ,Female ,Seasons ,medicine.symptom ,business ,Multiplex Polymerase Chain Reaction - Abstract
Sapovirus is a common cause of acute gastroenteritis in all age groups. Sapovirus infections are seldom investigated in Spain, and its epidemiology in the country is not well known. The use of molecular diagnostic procedures has allowed a more frequent detection of sapoviruses in patients with diarrhea. A total of 2545 stool samples from patients with acute gastroenteritis attended from June 2018 to February 2020 at the Clinic University Hospital in Valencia, Spain, were analyzed by reverse transcription (RT) and real-time multiplex PCR (RT-PCR) to investigate the etiology of enteric infections. Sapovirus was the second enteric virus detected with a positive rate of 8%, behind norovirus (12.2%) and ahead of rotavirus (7.1%), astrovirus (4.9%) and enteric adenoviruses (2.9%). Most sapovirus infections occurred in infants and young children under 3 years of age (74%) with the highest prevalence in autumn and early winter. Coinfections were found in 25% of the patients with sapovirus diarrhea, mainly with other enteric viruses. Genotyping demonstrated the circulation of seven different genotypes during the study period, with a predominance of genotypes GI.1, GI.2, and GII.1. Phylogenetic analysis showed that genogroup GII strains form a cluster separated from genogroup GI and GV, being genotype GV.1 strains related to genotype GI.1 and GI.2 strains.
- Published
- 2021
- Full Text
- View/download PDF
24. ¿Es la enfermedad pulmonar obstructiva crónica un factor protector en la infección por SARS-CoV-2? La importancia del tratamiento broncodilatador
- Author
-
R. Boixeda, L. Campins, J. Juanola, L. Force, J. Oyon, M. Ferrer, A. Llinares, A. Arkesteijn, A. Erraiz, T. Rejon, E. Igual, M. Carmona, A. Muñoz, P. Prado, A. Ventura, B. Ferreiro, E. Guanyabens, L. Pérez, A. Sanchez, J. Delgado, M. Bitlloch, N. Morón, F. Sancho, A. Oller, C. Borrellas, E. Plensa, R. Arànega, C. Lopera, L. Arbonés, J. Fernández, A. Rex, M. Parra, A. Serrallonga, M.F. Solano, M. Larrousse, M. Mauri, C. Falgà, S. Bacca, P. Fernández, L. Pacho, M. Martin, A. Robles, X. Vilà, L. Ovejero, P. Ortega, S. Martínez, I. Ortiz, A. Vidal, P. Calderón, J. Baena, I. Badia, and A. Ruiz
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,medicine.drug_class ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Protective factor ,Pulmonary disease ,General Medicine ,medicine.disease_cause ,Virology ,Article ,Bronchodilator ,medicine ,business ,Coronavirus - Published
- 2020
- Full Text
- View/download PDF
25. Letter to the Editor Regarding 'Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation'
- Author
-
Sameem Abedin, Bronwen E. Shaw, Saurabh Chhabra, Tirsa M. Ferrer Marrero, Mary Beth Graham, and Parameswaran Hari
- Subjects
Letter to the editor ,Coronavirus disease 2019 (COVID-19) ,Bone marrow transplantation ,medicine.medical_treatment ,Pneumonia, Viral ,Hematopoietic stem cell transplantation ,medicine.disease_cause ,Article ,Cell therapy ,Betacoronavirus ,COVID-19 Testing ,medicine ,Humans ,Pandemics ,Immunocompromise ,Coronavirus ,Transplantation ,Hematopoietic cell transplantation ,medicine.diagnostic_test ,Hematopoietic cell ,business.industry ,Clinical Laboratory Techniques ,SARS-CoV-2 ,Hematopoietic Stem Cell Transplantation ,COVID-19 ,Hematology ,respiratory tract diseases ,medicine.anatomical_structure ,Bronchoalveolar lavage ,surgical procedures, operative ,Severe acute respiratory syndrome ,Immunology ,business ,Coronavirus Infections ,Respiratory tract - Abstract
The full impact of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), on the field of hematopoietic cell transplantation (HCT) is unknown. This perspective paper reviews the following: current COVID-19 epidemiology, diagnosis, and potential therapies; care considerations unique to HCT recipients; and the concept of a learning network to assimilate emerging guidelines and best practices and to optimize patient outcomes through facilitating shared learning and experience across transplantation centers.
- Published
- 2020
26. Neuropilin-2, the Specific Binding Partner to ATYR1923, Is Expressed in Sarcoid Granulomas and Key Immune Cells
- Author
-
S. Paz, D. Chu, C. Burkart, J. Ampudia, S. Rosengren, S. Crampton, M. Ferrer, and L. Nangle
- Subjects
Neuropilin-2 ,Immune system ,business.industry ,Key (cryptography) ,Medicine ,business ,Cell biology - Published
- 2020
27. Validation of the PES Prediction Score for the Causative Different to Treat Microorganisms in Community-Acquired Pneumonia
- Author
-
Catia Cillóniz, Albert Gabarrus, M.-C. de la Torre, Santiago Ewig, Rosario Menéndez, Elena Prina, Otavio T. Ranzani, J. Almirall, M. Ferrer Monreal, Raúl Méndez, Adrian Ceccato, and Ariela da Silva Torres
- Subjects
medicine.medical_specialty ,Prediction score ,Community-acquired pneumonia ,business.industry ,Internal medicine ,medicine ,medicine.disease ,business - Published
- 2020
28. MON-LB74 The Problem of Measuring 1,25(OH)2 Vitamin D in Patients With High Levels of 25(OH) Vitamin D
- Author
-
Karina Helena Morais Cardozo, Guilherme Goncalves Okai, José Gilberto H. Vieira, and Cláudia M. Ferrer
- Subjects
medicine.medical_specialty ,Endocrinology ,Chemistry ,Endocrinology, Diabetes and Metabolism ,Internal medicine ,Bone and Mineral Metabolism ,Vitamin D and neurology ,medicine ,In patient ,Clinical Aspects of Osteoporosis and Vitamin D Action ,AcademicSubjects/MED00250 - Abstract
Recently, the use of Vitamin D in high doses for treatment of several conditions, mainly autoimmune in nature, has been advocated with dubious results. Hypercalcemia is an important side effect of this intervention. Here we describe our findings in samples that presented 25(OH)D in excess of 150 ng/mL (375 nmol/L) and had 1,25(OH)2D also measured. Material and Methods: we used serum samples from our diagnostic routine, received for measurement of 25(OH)D and 1,25(OH)2D according to medical requisition. A first group (group A) included 213 samples collected up to November 2018, used Diasorin’s chemiluminescent assays for 25OHD and 1,25(OH)2D, and a second group (group B), comprising 88 samples, used the same 25(OH)D assay and LC-MS/MS method for 1,25(OH)2D. 1,25(OH)2D measurement in the group A used a chemiluminescent competitive assay (Liason XL, Diasorin). The 1,25(OH)2D LC-MS/MS assay includes a previous sample prep, extraction, derivatization and chromatrography. APCI+ is followed by SRM (Selected Reaction Monitoring) and CAD (Collision Activated Dissociation) fragmentation. Precision studies showed, between run CVs of 6.8% to 7.4% and within run of 2.9% to 5.5%. In vitro investigations testing standards and spiked samples with 25(OH)D3, 25(OH)D2, 3-epimer-25(OH)D3 and 24R,25(OH)2D3 were also used to verify possible analytical interferences in the 1,25(OH)2D LC-MS/MS. Results: in group A, 25(OH)D median was 371 ng/mL (928 nmol/L), range 154 ng/mL to 856 ng/mL; 1,25(OH)2D median of 350 pg/mL (875 pmol/L), range 41 pg/mL to 1280 pg/mL. Correlation (Spearman) between 25(OH)D and 1,25(OH)2 was r= 0.8649 (P In group A 189 samples had calcium measurement (median 9.7 mg/dL, range of 8.7 to 13.6 mg/dL), 182 creatinine (median of 0.8 mg/dL range of 0.3 to 1.8 mg/dL) and 179 PTH (median 19 pg/mL, range 5 to 68 pg/mL). In group B 75 cases had measurements of calcium (median 9.7, range 8.6 to 16.6 mg/dL), 75 of creatinine (median 0.8, range 0.3 to 2.5 mg/dL) and 75 of PTH (median 20, range 9 to 49 pg/mL). The in vitro tests showed a slight interference from 25(OH)D3, 3-epimer-25(OH)D3 and 24R,25(OH)2D3 molecules in the LC-MS/MS method. Conclusion: our results confirm data already published showing interference of high levels of 25(OH)D in 1,25(OH)2D measured by immunoassay and, in a milder way, by LC-MS/MS (1). V. Care should be taken in the interpretation of 1,25(OH)2D values in samples with high 25(OH)D values. 1. Hawkes CP, Schnellbacher S, Singh RJ, Levine MA. 25-Hydroxyvitamin D can interfere with a common assay for 1,25-dihydroxyvitamin D in vitamin D intoxication. J Clin Endocrinol Metab. 2015; 100:2883-2889.
- Published
- 2020
29. Maxillary Implant-Supported Overdentures: Mechanical Behavior Comparing Individual Axial and Bar Retention Systems. A Cohort Study of Edentulous Patients
- Author
-
María Fernanda Solá-Ruíz, Eduardo Selva-Otaolaurruchi, Carlos Labaig-Rueda, Lucía Fernández-Estevan, J. M. Ferrer, and Rubén Agustín-Panadero
- Subjects
Male ,Medicine (General) ,Dental Wear ,Dentistry ,overdenture ,ODB++ ,Article ,bar ,Cohort Studies ,Dental Prosthesis Retention ,locator ,03 medical and health sciences ,R5-920 ,0302 clinical medicine ,Patient satisfaction ,Surveys and Questionnaires ,medicine ,Humans ,Dental Restoration Failure ,Prospective Studies ,Prospective cohort study ,Aged ,Mechanical Phenomena ,Dental Implants ,Edentulism ,business.industry ,030206 dentistry ,medicine.disease ,Denture, Overlay ,clinical outcomes ,Treatment Outcome ,Screw loosening ,Patient Satisfaction ,Automotive Engineering ,dental implants ,Female ,Dental Prosthesis, Implant-Supported ,Mouth, Edentulous ,business ,030217 neurology & neurosurgery ,Implant supported ,Cohort study ,Follow-Up Studies - Abstract
Background and objectives: To compare the medium- to long-term mechanical behavior of overdentures with two different retention systems: overdentures with Locator®, axial retention, and vertical insertion overdentures with bar retention, used to rehabilitate edentulous maxillar. Material and Methods: This prospective study assessed patients presenting complete maxillary edentulism, rehabilitated by means of implant-supported overdentures (n = 20), 10 with Locator®, axial retention (ODA group) and 10 with overdentures on bars (ODB group). Patients also completed a questionnaire to determine their satisfaction with treatment. Results: The mean follow-up time in both groups was 11.4 years, with follow-up times in both groups ranging from 5 to 14 years. The ODA group suffered mechanical complications such as retention loss, need for nylon retention insert changes, resin fracture, and need for relining. In the ODB group, prosthetic dental wear, screw loosening, and complete prosthetic failure were more common. A total of 19 implants failed (23.8%), of these, 11 were in the ODA group (failure rate = 27.5%) and eight in the ODB group (failure rate = 20%). The patient satisfaction questionnaire obtained a mean score of 7.9 out of 10 in the ODA group, and 9.75 in the ODB group. Conclusions: in rehabilitations of edentulous maxillar by means of implant-supported overdentures, both the systems assessed were shown to be effective in the medium to long term. Patients expressed a high level of satisfaction with the treatments received.
- Published
- 2020
30. Bayesian networks established functional differences between breast cancer subtypes
- Author
-
Guillermo Prado-Vázquez, Juan Ángel Fresno Vara, Lucía Trilla-Fuertes, Rocío López-Vacas, Pilar Zamora, Hilario Navarro, Jorge M. Arevalillo, Paolo Nanni, Enrique Espinosa, Elena López-Camacho, Angelo Gámez-Pozo, Andrea Zapater-Moros, M. Ferrer-Gomez, Mariana Díaz-Almirón, and Paloma Main
- Subjects
0301 basic medicine ,Oncology ,Proteomics ,Disease ,Directed Acyclic Graphs ,Biochemistry ,Extracellular matrix ,Database and Informatics Methods ,0302 clinical medicine ,Breast Tumors ,Medicine and Health Sciences ,Receptor ,Extracellular Matrix Proteins ,Multidisciplinary ,Directed Graphs ,Proteomic Databases ,Prognosis ,Extracellular Matrix ,030220 oncology & carcinogenesis ,Cohort ,Physical Sciences ,Medicine ,Cellular Structures and Organelles ,Research Article ,medicine.medical_specialty ,Computer and Information Sciences ,Science ,Context (language use) ,Breast Neoplasms ,Biology ,Research and Analysis Methods ,03 medical and health sciences ,Breast cancer ,Internal medicine ,Breast Cancer ,medicine ,Humans ,Cancers and Neoplasms ,Biology and Life Sciences ,Proteins ,Bayes Theorem ,Cell Biology ,medicine.disease ,Extracellular Matrix Composition ,030104 developmental biology ,Biological Databases ,Gene Ontology ,Graph Theory ,Function (biology) ,Mathematics - Abstract
Breast cancer is a heterogeneous disease. In clinical practice, tumors are classified as hormonal receptor positive, Her2 positive and triple negative tumors. In previous works, our group defined a new hormonal receptor positive subgroup, the TN-like subtype, which had a prognosis and a molecular profile more similar to triple negative tumors. In this study, proteomics and Bayesian networks were used to characterize protein relationships in 96 breast tumor samples. Components obtained by these methods had a clear functional structure. The analysis of these components suggested differences in processes such as mitochondrial function or extracellular matrix between breast cancer subtypes, including our new defined subtype TN-like. In addition, one of the components, mainly related with extracellular matrix processes, had prognostic value in this cohort. Functional approaches allow to build hypotheses about regulatory mechanisms and to establish new relationships among proteins in the breast cancer context., PLoS ONE, 15 (6), ISSN:1932-6203
- Published
- 2020
31. Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer
- Author
-
Emmanuelle Nicolas, Lauren S. Fink, Mauricio J. Reginato, Alexander Strigun, Alexander Beatty, Timothy P. Moran, Kathy Q. Cai, Jeffrey R. Peterson, Ulrike Rennefahrt, Tanu Singh, Christina M. Ferrer, and Erik Peter
- Subjects
0301 basic medicine ,Cancer Research ,Triple Negative Breast Neoplasms ,Biology ,Pharmacology ,Transfection ,Article ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,Breast cancer ,Metabolomics ,Mice, Inbred NOD ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Molecular Targeted Therapy ,RNA, Small Interfering ,Triple-negative breast cancer ,Cancer ,Glutathione ,medicine.disease ,Biosynthetic Pathways ,Metabolic pathway ,030104 developmental biology ,Oncology ,chemistry ,Cancer cell ,Heterografts ,Keratins ,Female ,Reactive Oxygen Species - Abstract
Cancer cells can exhibit altered dependency on specific metabolic pathways and targeting these dependencies is a promising therapeutic strategy. Triple-negative breast cancer (TNBC) is an aggressive and genomically heterogeneous subset of breast cancer that is resistant to existing targeted therapies. To identify metabolic pathway dependencies in TNBC, we first conducted mass spectrometry–based metabolomics of TNBC and control cells. Relative levels of intracellular metabolites distinguished TNBC from nontransformed breast epithelia and revealed two metabolic subtypes within TNBC that correlate with markers of basal-like versus non-basal–like status. Among the distinguishing metabolites, levels of the cellular redox buffer glutathione were lower in TNBC cell lines compared to controls and markedly lower in non-basal–like TNBC. Significantly, these cell lines showed enhanced sensitivity to pharmacologic inhibition of glutathione biosynthesis that was rescued by N-acetylcysteine, demonstrating a dependence on glutathione production to suppress ROS and support tumor cell survival. Consistent with this, patients whose tumors express elevated levels of γ-glutamylcysteine ligase, the rate-limiting enzyme in glutathione biosynthesis, had significantly poorer survival. We find, further, that agents that limit the availability of glutathione precursors enhance both glutathione depletion and TNBC cell killing by γ-glutamylcysteine ligase inhibitors in vitro. Importantly, we demonstrate the ability to this approach to suppress glutathione levels and TNBC xenograft growth in vivo. Overall, these findings support the potential of targeting the glutathione biosynthetic pathway as a therapeutic strategy in TNBC and identify the non-basal-like subset as most likely to respond. Mol Cancer Ther; 17(1); 264–75. ©2017 AACR.
- Published
- 2018
32. Impact of insulin therapy before donation on graft outcomes in pancreas transplantation: An analysis of the OPTN/UNOS database
- Author
-
Enrique Montagud-Marrahi, Fritz Diekmann, Vicens Torregrosa, Mireia Musquera, Enric Esmatjes, David Cucchiari, Josep M. Campistol, Nuria Esforzado, Antonio J. Amor, Alicia Molina-Andujar, María José Ramírez-Bajo, Joaquim Casals, Federic Oppenheimer, J. M. Ferrer, Frederic Cofan, Pedro Ventura-Aguiar, Beatriu Bayés, and Ignacio Revuelta
- Subjects
medicine.medical_specialty ,Surgical complication ,business.industry ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Insulin ,Patient survival ,General Medicine ,Pancreas transplantation ,medicine.disease ,Gastroenterology ,Endocrinology ,medicine.anatomical_structure ,Internal medicine ,Donation ,Diabetes mellitus ,Internal Medicine ,medicine ,Humans ,Pancreas Transplantation ,business ,Pancreas ,Kidney transplantation - Abstract
Aims Information on the impact of insulin therapy before pancreas donation on pancreas outcomes is scarce. We aim to explore the influence of insulin therapy before donation on recipient and pancreas graft survival. Methods Registry study including 12,841 pancreas recipients from the OPTN/UNOS registry performed between 2000 and 2017. Inverse probability of treatment weighting (IPTW) was used to account for covariate imbalance between recipients from a donor with and without insulin requirements. Results A total of 7765 (60%) patients received a pancreas from a donor with insulin before donation (IBD). Pancreas graft survival (death-censored) was similar between recipients from IBD and non-IBD donors at 1, 5 and 10 years (89% vs 89%, 78% vs 79 and 69% vs 70%, respectively, P = 0.35). Recipients from IBD donors presented a similar 90-days pancreas graft survival. After IPTW weighting, IBD donors were neither associated with any post-transplant surgical complication (HR 1.11 [95% CI 0.98–1.24], P = 0.06), nor with risk for recipient death (HR 0.94 [95% CI 0.85–1.04], P = 0.26), nor pancreas graft failure (HR 1.06 [95% CI 0.98–1.16], P = 0.15). Conclusions Insulin therapy before donation in accepted pancreas donors was not associated, per se, with an impaired pancreas graft and patient survival.
- Published
- 2021
33. P.136: Impact of Insulin Therapy in Pancreas Transplantation Donors on Graft Outcomes: An Analysis of the OPTN/UNOS Database
- Author
-
Mireia Musquera, Yiliam Fundora, Fritz Diekmann, Pedro Ventura-Aguiar, Fabio Ausania, Ignacio Revuelta, Enrique Montagud-Marrahi, J. M. Ferrer, Jordi Rovira, Enric Esmatjes, David Cucchiari, Antonio J. Amor, and Constantino Fondevila
- Subjects
Transplantation ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Insulin ,Urology ,Medicine ,Pancreas transplantation ,business - Published
- 2021
34. 649: Pharmacologic response of rare CFTR folding variants is mediated by a silent polymorphism that alters ribosome velocity
- Author
-
Robert Rauscher, D. Joshi, Giovana B Bampi, L. Strug, M. Ballman, M. Ferrer, Eric J. Sorscher, Kathryn E. Oliver, J. Rommens, D. Mark, and Zoya Ignatova
- Subjects
Pulmonary and Respiratory Medicine ,Folding (chemistry) ,Genetics ,Polymorphism (computer science) ,business.industry ,Pediatrics, Perinatology and Child Health ,medicine ,medicine.disease ,business ,Ribosome ,Cystic fibrosis - Published
- 2021
35. AB0092 ANTISYNTHETASE SYNDROME: CLINICAL PROFILE, SEROLOGIC AND TREATMENTS USED IN A COHORT OF PATIENTS FOLLOWED AT THE VIRGEN MACARENA HOSPITAL
- Author
-
M. Ferrer Galván, I. García Hernández, L. Fernández de la Fuente Bursón, J. J. Pérez Venegas, F. J. Toyos Sáenz de Miera, and P. Muñoz Reinoso
- Subjects
Pediatrics ,medicine.medical_specialty ,Rheumatology ,business.industry ,Immunology ,Cohort ,medicine ,Immunology and Allergy ,Antisynthetase syndrome ,medicine.disease ,business ,General Biochemistry, Genetics and Molecular Biology ,Serology - Abstract
Background:The antisynthetase syndrome (SAS) is characterized by the presence of antisynthetase antibodies, anti-JO1, PL7 y PL12 are the most common; and the classic triad of myositis, arthritis, and diffuse interstitial lung disease (ILD)1. Most patients present incomplete forms and the severity of the ILD determines the prognosis of the disease2.Objectives:to analyze epidemiological, clinical and serological characteristics and treatments used in a cohort of patients with SAS.Methods:descriptive study of review of medical records. Data were collected from 15 patients with SAS followed in the Rheumatology and Pneumology consultations of the Virgen Macarena Hospital (Seville) in the last 10 years. The analysis was carried out using the R software.Results:15 patients were included, 8 men and 7 women. The median age was 56 years (33-77). Seven patients (47%) used to smoke. Four patients (27%) met the classical triad. All of them presented ILD and 8 patients (53%) had arthritis and / or myositis. Five (33%) had mechanic’s hands and six of them (40%) presented Raynaud. Seven (47%) suffered from dyspnea before the SAS diagnosis. The median diagnostic delay was 1 month (0-43). Seven (47%) patients had anti-JO1, 1 (7%) anti-PL7, 2 (13%) anti-PL12 and 2 (13%) patients anti-Ro52. Radiological patterns detected by HRCT were: 5 (33%) NINE, 4 (37%) NIU and 6 (40%) others. The initial treatment included mostly (66%) glucocorticoids (GC) and one or more cFAME. In maintenance, mycophenolate was used in 7 patients (47%), cyclosporine 5 (33%), cyclophosphamide in 3 cases (20%), azathioprine in 3 patients (20%) and methotrexate in 3 of them (20%). Four (37%) patients required a combination of DMARDs and 2 cases needed (13%) biological therapy, Rituximab and Tocilizumab. Changes in the mean value of the initial respiratory function tests (FVC1 and DLCO1) and during follow-up (FVC2 and DLCO2) were not relevant (FVC1 81.5% [42-110], FVC2 81% [59-115]; DLCO1 83% [10-112], DLCO2 80.5% [47-108]). Nine patients (60%) remained clinically stable and 3 patients (20%) progressed radiologically. Four patients died from ILD progression.Conclusion:In this study, the incomplete diagnosis of SAS predominated. The most detected antibody was anti-JO1. ILD is present in all cases, with NINE being the most frequent pattern so multidisciplinary management is necessary. Most used treatments were GC and FAMES combined, some cases required biological therapy.References:[1]Irazoque F, et al. Epidemiology, etiology and classification. Reumatol Clin. 2009;5:2-5.[2]Johnson C, et al. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med. 2014; 108(10):1542-8.Disclosure of Interests:None declared
- Published
- 2021
36. Nutrient sensor O-GlcNAc transferase controls cancer lipid metabolism via SREBP-1 regulation
- Author
-
Joyce V. Lee, Mircea Ivan, Valerie L. Sodi, Dimpi Mukhopadhyay, Zachary A. Bacigalupa, Mauricio J. Reginato, Kathryn E. Wellen, Wiktoria A. Gocal, and Christina M. Ferrer
- Subjects
0301 basic medicine ,Cancer Research ,ACLY ,Mice, Nude ,Apoptosis ,Breast Neoplasms ,Biology ,N-Acetylglucosaminyltransferases ,medicine.disease_cause ,Article ,Mice ,03 medical and health sciences ,lipid metabolism ,Biomarkers, Tumor ,Tumor Cells, Cultured ,Genetics ,medicine ,cancer ,Animals ,Humans ,Protein kinase A ,Molecular Biology ,Transcription factor ,lipogenesis ,SREBP-1 ,Cell Proliferation ,Regulation of gene expression ,Lipid metabolism ,Nutrients ,FAS ,Lipids ,Xenograft Model Antitumor Assays ,Sterol regulatory element-binding protein ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Biochemistry ,O-GlcNAc ,OGT ,Sterol Regulatory Element Binding Protein 1 ,Female ,lipids (amino acids, peptides, and proteins) ,Signal transduction ,Carcinogenesis ,Signal Transduction - Abstract
Elevated O-GlcNAcylation is associated with disease states such as diabetes and cancer. O-GlcNAc transferase (OGT) is elevated in multiple cancers and inhibition of this enzyme genetically or pharmacologically inhibits oncogenesis. Here we show that O-GlcNAcylation modulates lipid metabolism in cancer cells. OGT regulates expression of the master lipid regulator the transcription factor sterol regulatory element binding protein 1 (SREBP-1) and its transcriptional targets both in cancer and lipogenic tissue. OGT regulates SREBP-1 protein expression via AMP-activated protein kinase (AMPK). SREBP-1 is critical for OGT-mediated regulation of cell survival and of lipid synthesis, as overexpression of SREBP-1 rescues lipogenic defects associated with OGT suppression, and tumor growth in vitro and in vivo. These results unravel a previously unidentified link between O-GlcNAcylation, lipid metabolism and the regulation of SREBP-1 in cancer and suggests a crucial role for O-GlcNAc signaling in transducing nutritional state to regulate lipid metabolism.
- Published
- 2017
37. Critically Ill and Newly Diagnosed HIV Patients
- Author
-
Tirsa M. Ferrer Marrero and Javeria Haque
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,Critically ill ,Hiv patients ,MEDLINE ,Medicine ,Newly diagnosed ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine ,business ,Intensive care medicine - Published
- 2020
38. A prospective randomized study of the efficacy of 'Turning Point,' an inpatient violence intervention program
- Author
-
Andrea van Zandt, Thomas A. Santora, Amy J. Goldberg, Jill Volgraf, Lars O. Sjoholm, Abhijit Pathak, Jay Dujon, Scott Charles, Lucas M. Ferrer, Frederick V. Ramsey, Catherine Loveland-Jones, and Joseph F. Rappold
- Subjects
Firearms ,medicine.medical_specialty ,Teachable moment ,Wounds, Stab ,Violence ,Critical Care and Intensive Care Medicine ,law.invention ,Hospitals, University ,03 medical and health sciences ,Hospitals, Urban ,0302 clinical medicine ,Patient Education as Topic ,Randomized controlled trial ,law ,medicine ,Humans ,Prospective randomized study ,Turning point ,Prospective Studies ,030212 general & internal medicine ,Psychiatry ,Philadelphia ,Inpatients ,Intervention program ,Social work ,business.industry ,Aggression ,Public health ,Standard of Care ,030208 emergency & critical care medicine ,Attitude ,Physical therapy ,Wounds, Gunshot ,Surgery ,medicine.symptom ,business - Abstract
From 2002 to 2011, there were more than 17,000 shootings in Philadelphia. "Turning Point," Temple University Hospital's inpatient violence intervention program, takes advantage of the teachable moment that occurs after violent injury. In addition to receiving traditional social work services, Turning Point patients watch their trauma bay resuscitation video and a movie about violence, meet with a gunshot wound survivor and an outpatient case manager, and also undergo psychiatric assessment. The purpose of this study was to determine the efficacy of Turning Point in changing attitudes toward guns and violence among victims of penetrating trauma.This prospective randomized study was conducted from January 2012 to January 2014. Patients who sustained a gunshot or stab wound were randomized to standard of care, which involved traditional social work services only, or Turning Point. The Attitudes Toward Guns and Violence Questionnaire was administered to assess attitude change. Analysis was performed with repeated-measures analysis of variance. A p0.05 was significant.A total of 80 of a potential 829 patients completed the study (40 standard of care, 40 Turning Point). The most common reason for exclusion was anticipated length of stay being less than 48 hours. The two groups were similar with respect to most demographics. Unlike the standard-of-care group, the Turning Point group demonstrated a 50% reduction in aggressive response to shame, a 29% reduction in comfort with aggression, and a 19% reduction in overall proclivity toward violence.Turning Point is effective in changing attitudes toward guns and violence among victims of penetrating trauma. Longer follow-up is necessary to determine if this program can truly be a turning point in patients' lives.Therapeutic/care management study, level II.
- Published
- 2016
39. Investigación epidemiológica en cáncer colorrectal: perspectiva, prospectiva y retos bajo la óptica de explotación del Big-Data
- Author
-
J.M. García Torrecillas, F. Rubio-Gil, Á Reina Duarte, and M Ferrer Márquez
- Subjects
03 medical and health sciences ,0302 clinical medicine ,business.industry ,030220 oncology & carcinogenesis ,Public Health, Environmental and Occupational Health ,Medicine ,030230 surgery ,Family Practice ,business - Published
- 2016
40. P4487Inhibition of aortic valve calcification by SNF472 in vitro
- Author
-
M. Bogdanova, Kåre-Olav Stensløkken, M Perez, Arnt E. Fiane, Mari-Liis Kaljusto, Carolina Salcedo, Jarle Vaage, M Ferrer, and Arsenii Zabirnyk
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Cardiology ,Aortic valve calcification ,Cardiology and Cardiovascular Medicine ,business ,In vitro - Abstract
Background Calcific aortic valve disease is the 2nd most frequent cause of open heart surgery. The valve interstitial cells (VIC) are crucial for calcification. SNF472 (a derivative of phytic acid) is a calcification inhibitor currently in clinical development for the treatment of cardiovascular calcification (Phase 2 CaLIPSO trial, EudraCT 2016–002834–59). SNF472 has been shown to inhibit vascular calcification in several preclinical models. Purpose 1. Establish a new model of calcification in cultured human VIC; 2. Investigate whether SNF472 would inhibit calcification in this model, and 3. Study if SNF472 might inhibit ongoing calcification processes. Methods Healthy and calcified aortic valves were obtained from heart transplant recipients and patients undergoing aortic valve replacement due to calcific valve disease, respectively. VIC were isolated and seeded in basic growth medium, osteogenic differentiation medium (Osteodiff) alone, and with addition of different concentrations of SNF472. The following series of studies were performed: 1. VIC from healthy and calcified valves were cultured for three weeks with Osteodiff; 2. VIC from calcified valves were cultured for 3 weeks in Osteodiff media with 0, 1, 3, 10, 30, or 100 μM SNF472; 3. VIC from calcified valves were cultured for 3 weeks in Osteodiff media in total, but after 1 or 2 weeks 30 or 100 μM SNF472 was added to the cultures (n=8). Calcification was visualized by Alzarin Red staining and quantified by spectrophotometry. Statistics analysis was performed nonparametric One-Way ANOVA (Friedman and Kruskal–Wallis tests) with Dunn's post-test. Results Calcification was found to be 30% stronger in cultures of VIC from calcified valves as compared to cultured VIC from healthy valves (p=0.03). SNF472 successfully inhibited VIC calcification in a dose-dependent manner. SNF472 concentrations of 1, and 3 μM inhibited calcification by 7% (not significant) and 66% (p=0.08) respectively. Concentrations of 10, 30, and 100 μM completely inhibited calcification. 30 and 100 μM of SNF472 added after 1 week reduced ongoing calcification by 84% (p Conclusions VIC from calcified valves have a more pro-calcification phenotype than VIC from healthy valves. SNF472 is able to inhibit the development VIC calcification in vitro. By early intervention SNF472 is also able to stop the progression of ongoing calcification. SNF472 shows to be a promising therapy to treat heart valve calcification. Acknowledgement/Funding EC FP7 (GA 609020), Balearic Islands Government grant (ES01/TCAI/41_2017), FEDER 2014-2020, Laboratoris Sanifit, Palma, Spain; University of Oslo
- Published
- 2019
41. The ESC ACCA EAPCI EORP acute coronary syndrome ST-elevation myocardial infarction registry
- Author
-
Zeymer, U., Ludman, P., Danchin, N., Kala, P., Maggioni, A. P., Weidinger, F, P Gale, C, Beleslin, B, Budaj, A, Chioncel, O, Dagres, N, Danchin, N, Emberson, J, Erlinge, D, Glikson, M, Gray, A, Kayikcioglu, M, P Maggioni, A, K Nagy, V, Nedoshivin, A, A-S, Petronio, Roos-Hesselink, J, Wallentin, L, Zeymer, U, Franz, Weidinger, Uwe, Zeymer, Nicolas, Danchin, Peter, Ludman, Peter, Sinnaeve, Petr, Kala, Roberto, Ferrari, Maggioni, Aldo P., Artan, Goda, Parounak, Zelveian, Kiril, Karamfilov, Zuzana, Motovska, Bent, Raungaard, Toomas, Marandi, Sameh Mohamed Shaheen, Rosa-Maria, Lidon, Pasi Paavo Karjalainen, Zviad, Kereselidze, Dimitrios, Alexopoulos, David, Becker, Martin, Quinn, Zaza, Iakobishvili, Hasan, Al-Farhan, Masoumeh, Sadeghi, Roberto, Caporale, Francesco, Romeo, Erkin, Mirrakhimov, Pranas, Serpytis, Andrejs, Erglis, Sasko, Kedev, Matthew Mercieca Balbi, Alice May Moore, Dariusz, Dudek, Jacek, Legutko, Jorge, Mimoso, Gabriel, Tatu-Chitoiu, Sinisa, Stojkovic, Evgeny, Shlyakhto, Khalid, F AlHabib, Matjaz, Bunc, Martin, Studencan, Mohamed Sami Mourali, Gani, Bajraktari, Marème, Konte, Florian, Larras, Elin Folkesson Lefrancq, Souad, Mekhaldi, Cécile, Laroche, Goda, A, Shuka, N, Pavli, E, Tafaj, E, Gishto, T, Dibra, A, Duka, A, Gjana, A, Kristo, A, Knuti, G, Demiraj, A, Dado, E, Hasimi, E, Simoni, L, Siqeca, M, Sisakian, H, Hayrapetyan, H, Markosyan, S, Galustyan, L, Arustamyan, N, Kzhdryan, H, Pepoyan, S, Zirkik, A, D Von Lewinski, Paetzold, S, Kienzl, I, Matyas, K, Neunteufl, T, Nikfardjam, M, Neuhold, U, Mihalcz, A, Glaser, F, Steinwender, C, Reiter, C, Grund, M, Hrncic, D, Hoppe, U, Hammerer, M, Hinterbuchner, L, Hengstenberg, C, G Delle Karth, Lang, I, Winkler, W, Hasun, M, Kastner, J, Havel, C, Derntl, M, Oberegger, G, Hajos, J, Adlbrecht, C, Publig, T, M-C, Leitgeb, Wilfing, R, Jirak, P, C-Y, Ho, Puskas, L, Schrutka, L, Spinar, J, Parenica, J, Hlinomaz, O, Fendrychova, V, Semenka, J, Sikora, J, Sitar, J, Groch, L, Rezek, M, Novak, M, Kramarikova, P, Stasek, J, Dusek, J, Zdrahal, P, Polasek, R, Karasek, J, Seiner, J, Sukova, N, Varvarovsky, I, Lazarák, T, Novotny, V, Matejka, J, Rokyta, R, Volovar, S, Belohlavek, J, Motovska, Z, Siranec, M, Kamenik, M, Kralik, R, Raungaard, B, Ravkilde, J, E Jensen, S, Villadsen, A, Villefrance, K, C Schmidt Skov, Maeng, M, Moeller, K, Hasan-Ali, H, A Ahmed, T, Hassan, M, Elguind, A, M Farouk Ismail, A Ibrahim Abd El-Aal, A El-sayed Gaafar, H Magdy Hassan, M Ahmed Shafie, M Nabil El-khouly, Bendary, A, Darwish, M, Ahmed, Y, Amin, O, Abdelhakim, A, Abosaif, K, Kandil, H, M A, G Galal, E El Hefny, E, M El Sayed, Aly, K, Mokarrab, M, Osman, M, Abdelhamid, M, Mantawy, S, R Ali, M, D Kaky, S, A Khalil, V, M E, A Saraya, Talaat, A, Nabil, M, M Mounir, W, Aransa, K. Mahmoud A., Kazamel, G, Anwar, S, Al-Habbaa, A, M Abd el Monem, Ismael, A, Amin Abu-Sheaishaa, M., M Abd Rabou, M, T M, A Hammouda, Moaaz, M, Elkhashab, K, Ragab, T, Rashwan, A, Rmdan, A, Abdelrazek, G, Ebeid, H, H Soliman Ghareeb, Farag, N, Zaki, M, Seleem, M, Torki, A, Youssef, M, A AlLah Nasser, N, Rafaat, A, Selim, H, M Makram, M, Khayyal, M, Malasi, K, Madkou, A, Kolib, M, Alkady, H, Nagah, A, Yossef, M, Wafa, A, Mahfouz, E, Faheem, G, M Magdy Moris, Ragab, A, Ghazal, M, Mabrouk, A, El-Masry, M, Naseem, M, Samir, S, Marandi, T, Reinmets, J, Allvee, M, Saar, A, Ainla, T, Vaide, A, Kisseljova, M, Pakosta, U, Eha, J, Lotamois, K, Sia, J, Myllymaki, J, Pinola, T, P Karjalainen, P, Paana, P, Mikkelsson, J, Ampio, M, Tsivilasvili, J, Zurab, P, Kereselidze, Z, Agladze, R, Melia, A, Gogoberidze, D, Khubua, N, Totladze, L, Metreveli, I, Chikovani, A, Eitel, I, Pöss, J, Werner, M, Constantz, A, Ahrens, C, Tolksdorf, H, Klinger, S, Sack, S, Heer, T, Lekakis, J, Kanakakis, I, Xenogiannis, I, Ermidou, K, Makris, N, Ntalianis, A, Katsaros, F, Revi, E, Kafkala, K, Mihelakis, E, Diakakis, G, Grammatikopoulos, K, Voutsinos, D, Alexopoulos, D, Xanthopoulou, I, Mplani, V, Foussas, S, Papakonstantinou, N, Patsourakos, N, Dimopoulos, A, Derventzis, A, Athanasiou, K, P Vassilikos, V, Papadopoulos, C, Tzikas, S, Vogiatzis, I, Datsios, A, Galitsianos, I, Koutsampasopoulos, K, Grigoriadis, S, Douras, A, Baka, N, Spathis, S, Kyrlidis, T, Hatzinikolaou, H, G Kiss, R, Becker, D, Nowotta, F, Tóth, K, Szabó, S, Lakatos, C, Jambrik, Z, Ruzsa, J, Ruzsa, Z, Róna, S, Toth, J, A Vargane Kosik, K S, B Toth, G Nagy, G, Ondrejkó, Z, Körömi, Z, Botos, B, Pourmoghadas, M, Salehi, A, Massoumi, G, Sadeghi, M, Soleimani, A, Sarrafzadegan, N, Roohafza, H, Azarm, M, Mirmohammadsadeghi, A, Rajabi, D, Rahmani, Y, Siabani, S, Najafi, F, Hamzeh, B, Karim, H, Siabani, H, Saleh, N, Charehjoo, H, Zamzam, L, Al-Temimi, T, Al-Farhan, H, Al-Yassin, A, Mohammad, A, Ridha, A, Al-Saedi, G, Atabi, N, Sabbar, O, Mahmood, S, Dakhil, Z, F Yaseen, I, Almyahi, M, Alkenzawi, H, Alkinani, T, Alyacopy, A, Kearney, P, Twomey, K, Iakobishvili, Z, Shlomo, N, Beigel, R, Caldarola, P, Rutigliano, D, L Sublimi Saponetti, Locuratolo, N, Palumbo, V, Scherillo, M, Formigli, D, Canova, P, Musumeci, G, Roncali, F, Metra, M, Lombardi, C, Visco, E, Rossi, L, Meloni, L, Montisci, R, Pippia, V, F Marchetti, M, Congia, M, Cacace, C, Luca, G, Boscarelli, G, Indolfi, C, Ambrosio, G, Mongiardo, A, Spaccarotella, C, S De Rosa, Canino, G, Critelli, C, Caporale, R, Chiappetta, D, Battista, F, Gabrielli, D, Marziali, A, Bernabò, P, Navazio, A, Guerri, E, Manca, F, Gobbi, M, Oreto, G, Andò, G, Carerj, S, Saporito, F, Cimmino, M, Rigo, F, Zuin, G, Tuccillo, B, F Scotto di Uccio, L Scotto di Uccio, Lorenzoni, G, Meloni, I, Merella, P, M Polizzi, G, Pino, R, Marzilli, M, Morrone, D, Caravelliorsini, P, Orsini, E, Mosa, S, Piovaccari, G, Santarelli, A, Cavazza, C, Romeo, F, Fedele, F, Mancone, M, Straito, M, Salvi, N, Scarparo, P, Severino, P, Razzini, C, Massaro, G, Cinque, A, Gaudio, C, Barillà, F, Torromeo, C, Porco, L, Mei, M, Lorio, R, Nassiacos, D, Barco, B, Sinagra, G, Falco, L, Priolo, L, Perkan, A, Strana, M, Bajraktari, G, Percuku, L, Berisha, G, Mziu, B, Beishenkulov, M, Abdurashidova, T, Toktosunova, A, Kaliev, K, Serpytis, P, Serpytis, R, Butkute, E, Lizaitis, M, Broslavskyte, M, G Xuereb, R, M Moore, A, M Mercieca Balbi, Paris, E, Buttigieg, L, Musial, W, Dobrzycki, S, Dubicki, A, Kazimierczyk, E, Tycinska, A, Wojakowski, W, Kalanska-Lukasik, B, Ochala, A, Wanha, W, Dworowy, S, Sielski, J, Janion, M, Janion-Sadowska, A, Dudek, D, Wojtasik-Bakalarz, J, Bryniarski, L, Z Peruga, J, Jonczyk, M, Jankowski, L, Klecha, A, Legutko, J, Michalowska, J, Brzezinski, M, Kozmik, T, Kowalczyk, T, Adamczuk, J, Maliszewski, M, Kuziemka, P, Plaza, P, Jaros, A, Pawelec, A, Sledz, J, Bartus, S, Zmuda, W, Bogusz, M, Wisnicki, M, Szastak, G, Adamczyk, M, Suska, M, Czunko, P, Opolski, G, Kochman, J, Tomaniak, M, Miernik, S, Paczwa, K, Witkowski, A, P Opolski, M, D Staruch, A, Kalarus, Z, Honisz, G, Mencel, G, Swierad, M, Podolecki, T, Marques, J, Azevedo, P, A Pereira, M, Gaspar, A, Monteiro, S, Goncalves, F, Leite, L, Mimoso, J, Manuel Lopes dos Santos, W., Amado, J, Pereira, D, Silva, B, Caires, G, Neto, M, Rodrigues, R, Correia, A, Freitas, D, Lourenco, A, Ferreira, F, Sousa, F, Portugues, J, Calvo, J, Almeida, F, Alves, M, Silva, A, Caria, R, Seixo, F, Militaru, C, Ionica, E, Tatu-Chitoiu, G, Istratoaie, O, Florescu, M, Lipnitckaia, E, Osipova, O, Konstantinov, S, Bukatov, V, Vinokur, T, Egorova, E, Nefedova, E, Levashov, S, Gorbunova, A, Redkina, M, Karaulovskaya, N, Bijieva, F, Babich, N, Smirnova, O, Filyanin, R, Eseva, S, Kutluev, A, Chlopenova, A, Shtanko, A, Kuppar, E, Shaekhmurzina, E, Ibragimova, M, Mullahmetova, M, Chepisova, M, Kuzminykh, M, Betkaraeva, M, Namitokov, A, Khasanov, N, Baleeva, L, Galeeva, Z, Magamedkerimova, F, Ivantsov, E, Tavlueva, E, Kochergina, A, Sedykh, D, Kosmachova, E, Skibitskiy, V, Porodenko, N, Litovka, K, Ulbasheva, E, Niculina, S, Petrova, M, Harkov, E, Tsybulskaya, N, Lobanova, A, Chernova, A, Kuskaeva, A, Kuskaev, A, Ruda, M, Zateyshchikov, D, Gilarov, M, Konstantinova, E, Koroleva, O, Averkova, A, Zhukova, N, Kalimullin, D, Borovkova, N, Tokareva, A, Buyanova, M, Khaisheva, L, Pirozhenko, T, Novikova, T, Yakovlev, A, Tyurina, T, Lapshin, K, Moroshkina, N, Kiseleva, M, Fedorova, S, Krylova, L, Duplyakov, D, Semenova, Y, Rusina, A, Ryabov, V, Syrkina, A, Demianov, S, Reitblat, O, Artemchuk, A, Efremova, E, Makeeva, E, Menzorov, M, Shutov, A, Klimova, N, Shevchenko, I, Elistratova, O, Kostyuckova, O, Islamov, R, Budyak, V, Ponomareva, E, U Ullah Jan, M Alshehri, A, Sedky, E, Alsihati, Z, Mimish, L, Selem, A, Malik, A, Majeed, O, Altnji, I, Alshehri, M, Aref, A, Alhabib, K, Aldosary, M, Tayel, S, M Abd AlRahman, N Asfina, K, G Abdin Hussein, Butt, M, N Markovic Nikolic, Obradovic, S, Djenic, N, Brajovic, M, Davidovic, A, Romanovic, R, Novakovic, V, Dekleva, M, Spasic, M, Dzudovic, B, Jovic, Z, Cvijanovic, D, Cvijanovic, S, Ivanov, I, Cankovic, M, Jarakovic, M, Kovacevic, M, Trajkovic, M, Mitov, V, Jovic, A, Hudec, M, Gombasky, M, Sumbal, J, Bohm, A, Baranova, E, Kovar, F, Samos, M, Podoba, J, Kurray, P, Obona, T, Remenarikova, A, Kollarik, B, Verebova, D, Kardosova, G, Studencan, M, Alusik, D, Macakova, J, Kozlej, M, Bayes-Genis, A, Sionis, A, C Garcia Garcia, R-M, Lidon, A Duran Cambra, C Labata Salvador, F Rueda Sobella, J Sans Rosello, M Vila Perales, T Oliveras Vila, M Ferrer Massot, Bañeras, J, Lekuona, I, Zugazabeitia, G, Fernandez-Ortiz, A, A Viana Tejedor, Ferrera, C, Alvarez, V, Diaz-Castro, O, M Agra-Bermejo, R, Gonzalez-Cambeiro, C, Gonzalez-Babarro, E, J Domingo-Del Valle, Royuela, N, Burgos, V, Canteli, A, Castrillo, C, Cobo, M, Ruiz, M, Abu-Assi, E, M Garcia Acuna, J, U., Zeymer, P., Ludman, N., Danchin, P., Kala, A. P., Maggioni, F., Weidinger, STEMI Investigators, Ac, and Spaccarotella, C.
- Subjects
Registrie ,medicine.medical_specialty ,Acute coronary syndrome ,Registry ,medicine.medical_treatment ,Cardiology ,Reperfusion therapy ,Retrospective Studie ,Medical ,medicine ,Humans ,cardiovascular diseases ,Myocardial infarction ,Registries ,Disease management (health) ,Acute Coronary Syndrome ,Societies, Medical ,Quality of Health Care ,Retrospective Studies ,Acca ,biology ,business.industry ,Health Policy ,Primary percutaneous coronary intervention ,Percutaneous coronary intervention ,Disease Management ,Retrospective cohort study ,medicine.disease ,biology.organism_classification ,primary percutaneous coronary intervention ,registry ,reperfusion therapy ,ST-elevation myocardial infarction ,Cardiac surgery ,Europe ,surgical procedures, operative ,Emergency medicine ,ST Elevation Myocardial Infarction ,Societies ,Cardiology and Cardiovascular Medicine ,business ,Human - Abstract
Aims The Acute Cardiac Care Association (ACCA)–European Association of Percutaneous Coronary Intervention (EAPCI) Registry on ST-elevation myocardial infarction (STEMI) of the EurObservational programme (EORP) of the European Society of Cardiology (ESC) registry aimed to determine the current state of the use of reperfusion therapy in ESC member and ESC affiliated countries and the adherence to ESC STEMI guidelines in patients with STEMI. Methods and results Between 1 January 2015 and 31 March 2018, a total of 11 462 patients admitted with an initial diagnosis of STEMI according to the 2012 ESC STEMI guidelines were enrolled. Individual patient data were collected across 196 centres and 29 countries. Among the centres, there were 136 percutaneous coronary intervention centres and 91 with cardiac surgery on-site. The majority of centres (129/196) were part of a STEMI network. The main objective of this study was to describe the demographic, clinical, and angiographic characteristics of patients with STEMI. Other objectives include to assess management patterns and in particular the current use of reperfusion therapies and to evaluate how recommendations of most recent STEMI European guidelines regarding reperfusion therapies and adjunctive pharmacological and non-pharmacological treatments are adopted in clinical practice and how their application can impact on patients’ outcomes. Patients will be followed for 1 year after admission. Conclusion The ESC ACCA-EAPCI EORP ACS STEMI registry is an international registry of care and outcomes of patients hospitalized with STEMI. It will provide insights into the contemporary patient profile, management patterns, and 1-year outcome of patients with STEMI.
- Published
- 2019
42. Spatial and temporal variations in Spain in the standardised ratio of in-hospital mortality due to colorectal cancer, 2008-2014
- Author
-
F. Rubio-Gil, María José Sánchez, M. Ferrer-Márquez, Miguel Rodríguez-Barranco, J. M. García-Torrecillas, M. C. Olvera-Porcel, [García-Torrecillas,JM, Ferrer-Márquez,M, Rubio-Gil,F] Hospital Universitario Torrecárdenas, Almería, Spain. [García-Torrecillas,JM, Sánchez,MJ, Rodríguez-Barranco,M] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Olvera-Porcel,MC] Fundación FIBAO, Hospital Universitario Torrecárdenas, Almería, Spain. [Sánchez,MJ, Rodríguez-Barranco,M] Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs, Granada, Spain. [Sánchez,MJ, Rodríguez-Barranco,M] Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain., and This work was supported by the Carlos III Institute of Health, Grant/Award Number [PI16/01931], Madrid (Spain) under the 2013–2016 National Plan for R&D&I, and by the ISCIII-General Subdirectorate for Evaluation and Promotion of Research, within the European Regional Development Fund (FEDER).
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Colorectal cancer ,Epidemiology ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,0302 clinical medicine ,Information Science::Information Science::Data Collection::Vital Statistics::Mortality [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Hospitalization::Length of Stay [Medical Subject Headings] ,Medicine ,Hospital Mortality ,Longitudinal Studies ,Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings] ,Standardised mortality ratio ,Aged, 80 and over ,Absolute risk reduction ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings] ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Christian ministry ,Female ,Neoplasias colorectales ,Colorectal Neoplasms ,Research Article ,Pais vasco ,medicine.medical_specialty ,Check Tags::Male [Medical Subject Headings] ,lcsh:RC254-282 ,03 medical and health sciences ,Spatio-Temporal Analysis ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies [Medical Subject Headings] ,Genetics ,Epidemiología ,Humans ,Mortality ,Aged ,Estimation ,Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings] ,In hospital mortality ,business.industry ,Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings] ,Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,Length of Stay ,medicine.disease ,030104 developmental biology ,Cross-Sectional Studies ,Check Tags::Female [Medical Subject Headings] ,Persons::Persons::Age Groups::Adult::Aged::Aged, 80 and over [Medical Subject Headings] ,Spain ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Spatial Analysis::Spatio-Temporal Analysis [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Hospital Mortality [Medical Subject Headings] ,Trends ,business ,Demography - Abstract
Background: Colorectal cancer (CRC) is the second cause of tumour mortality in Spain and Europe. To date, no studies have been conducted in Spain to evaluate the spatial and temporal distribution of the excess risk of death during hospitalisation for CRC. Methods: A cohort was constructed of all episodes of hospitalisation in Spain due to CRC (codes 153 and 154 of the International Classification of Diseases, 9th edition, Clinical Modification) during the period 2008-2014, based on the minimum basic data set published by the Ministry of Health. Mortality ratios were calculated per region for each of the years analyzed (spatial or cross-sectional analysis) and during the overall study period, for each region independently (temporal or longitudinal analysis). In the first of these analyses, particular note was taken of the regions and years in which the limits of two and three standard deviations were exceeded. Results: Two hundred and fifty eight thousand, nine hundred and twenty seven episodes of CRC were analysed. The patients were predominantly male (60.6%), with an average hospital stay of 13.16 days. Half underwent surgery during admission and on average presented more than six diagnoses at discharge. The spatial analysis revealed mortality ratios that deviated by at least three standard deviations in the following regions: Islas Canarias, Asturias, Valencia, Extremadura, País Vasco and Andalucía. The longitudinal analysis showed that most regions presented one or more years when CRC mortality was at least 15% higher than expected during the period; outstanding in this respect were Asturias, Navarra and La Rioja, where this excess risk was detected in at least 2 years. Conclusions: Geographic and temporal patterns of the distribution of the excess risk of mortality from CRC in Spain are described using SMRs. We conclude that during the study period, the geographic pattern of mortality in Spain did not coincide with the excess risk of mortality calculated using the SMR method described by Jarman and Foster. This method of risk estimation can be a useful tool for the study of mortality risk and its spatial variations. Yes
- Published
- 2019
43. Tumor-infiltrating Lymphocytes Expression in Stage IIIc/IV of High-grade Serous Ovarian Cancer: Variation with Neoadjuvant Chemotherapy and Prognostic Value
- Author
-
K. Rojas, J L Rodriguez, Luis Paz-Ares, Andrea Zapater-Moros, R. García-Martín, Lucía Trilla-Fuertes, Guillermo Prado-Vázquez, A. Maroto, C Barcena, J.A. Fresno Vara, L. Lema, Angelo Gámez-Pozo, M. Ferrer-Gomez, and Cesar Mendiola
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,Tumor-infiltrating lymphocytes ,Internal medicine ,medicine.medical_treatment ,medicine ,Serous ovarian cancer ,Stage IIIC ,Biology ,Neo adjuvant chemotherapy ,Ovarian cancer ,medicine.disease - Published
- 2019
44. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses
- Author
-
Jaime Feliu, Hilario Navarro, Juan Ángel Fresno Vara, Jorge M. Arevalillo, Mariana Díaz-Almirón, Enrique Espinosa, Pilar Zamora, Angelo Gámez-Pozo, Lucía Trilla-Fuertes, M. Ferrer-Gomez, Paloma Main, Guillermo Prado-Vázquez, Andrea Zapater-Moros, and Rocío López-Vacas
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,lcsh:Medicine ,Triple Negative Breast Neoplasms ,Kaplan-Meier Estimate ,Disease ,Article ,03 medical and health sciences ,Basal (phylogenetics) ,0302 clinical medicine ,Immune system ,Breast cancer ,Text mining ,Cancer stem cell ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Databases, Genetic ,medicine ,Cluster Analysis ,Humans ,lcsh:Science ,Triple-negative breast cancer ,Regulation of gene expression ,Multidisciplinary ,business.industry ,lcsh:R ,Models, Theoretical ,Prognosis ,medicine.disease ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Female ,lcsh:Q ,Neoplasm Grading ,business ,030217 neurology & neurosurgery - Abstract
Triple-negative breast cancer is a heterogeneous disease characterized by a lack of hormonal receptors and HER2 overexpression. It is the only breast cancer subgroup that does not benefit from targeted therapies, and its prognosis is poor. Several studies have developed specific molecular classifications for triple-negative breast cancer. However, these molecular subtypes have had little impact in the clinical setting. Gene expression data and clinical information from 494 triple-negative breast tumors were obtained from public databases. First, a probabilistic graphical model approach to associate gene expression profiles was performed. Then, sparse k-means was used to establish a new molecular classification. Results were then verified in a second database including 153 triple-negative breast tumors treated with neoadjuvant chemotherapy. Clinical and gene expression data from 494 triple-negative breast tumors were analyzed. Tumors in the dataset were divided into four subgroups (luminal-androgen receptor expressing, basal, claudin-low and claudin-high), using the cancer stem cell hypothesis as reference. These four subgroups were defined and characterized through hierarchical clustering and probabilistic graphical models and compared with previously defined classifications. In addition, two subgroups related to immune activity were defined. This immune activity showed prognostic value in the whole cohort and in the luminal subgroup. The claudin-high subgroup showed poor response to neoadjuvant chemotherapy. Through a novel analytical approach we proved that there are at least two independent sources of biological information: cellular and immune. Thus, we developed two different and overlapping triple-negative breast cancer classifications and showed that the luminal immune-positive subgroup had better prognoses than the luminal immune-negative. Finally, this work paves the way for using the defined classifications as predictive features in the neoadjuvant scenario.
- Published
- 2019
45. COVID-19 and lockdown impact on BPD patients and their familiars
- Author
-
M. Roca Santos, A. Vilaregut Puigdesens, N. Calvo Piñero, T. Pretel Luque, E. Castell Panisello, Z. Nieto Fernandez, and M. Ferrer Vinardell
- Subjects
education.field_of_study ,media_common.quotation_subject ,Population ,Familiar spirit ,medicine.disease ,Focus group ,Psychiatry and Mental health ,Content analysis ,Perception ,Pandemic ,medicine ,Psychology ,education ,Borderline personality disorder ,media_common ,Clinical psychology ,Qualitative research - Abstract
IntroductionIt is large known that Coronavirus outbreak has had a psychological impact on the general population, specifically on those with a mental disease as Borderline Personality Disorder (BPD) and their relatives.ObjectivesThe aim of the study is to identify and examine the individual and familiar impact of the coronavirus outbreak on patients diagnosed with BPD and their parents.Methods A qualitative research design using focus groups was selected to identify and discuss participants’ experiences, beliefs, perceptions and attitudes. The target population consisted of patients with BPD and their parents. Participants were recruited from the BPD psychiatric service from the Hospital Universitari de la Vall de Hebron (Barcelona, Spain). Data was collected via two focus groups, one with patients with BPD and other with their parents. Content analysis was used to determine categories and themes.ResultsThe qualitative analysis of participants’ perceptions are presented using the following themes: changes and difficulties during lockdown, after lockdown concerns and challenges, general learning, and future needs. Results identify factors associated with the COVID-19 outbreak and other factors already present as family dynamics and individual difficulties.Conclusions Findings have been discussed focusing on individual and familiar impact, and allows us to consider challenges precipitated by the COVID-19 pandemic. The study evidence that a family intervention approach is essential to enhance BPD treatment.
- Published
- 2021
46. ESICM LIVES 2016: part one
- Author
-
L. Bos, L. Schouten, L. van Vught, M. Wiewel, D. Ong, O. Cremer, A. Artigas, I. Martin-Loeches, A. Hoogendijk, T. van der Poll, J. Horn, N. Juffermans, M. Schultz, N. de Prost, T. Pham, G. Carteaux, A. Mekontso Dessap, C. Brun-Buisson, E. Fan, G. Bellani, J. Laffey, A. Mercat, L. Brochard, B. Maitre, LUNG SAFE investigators and the ESICM study group, P. A. Howells, D. R. Thickett, C. Knox, D. P. Park, F. Gao, O. Tucker, T. Whitehouse, D. F. McAuley, G. D. Perkins, LUNG SAFE Investigators and the ESICM Trials Group, L. Pisani, J. P. Roozeman, F. D. Simonis, A. Giangregorio, L. R. Schouten, S. M. Van der Hoeven, A. Serpa Neto, E. Festic, A. M. Dondorp, S. Grasso, L. D. Bos, M. J. Schultz, M. Koster-Brouwer, D. Verboom, B. Scicluna, K. van de Groep, J. Frencken, M. Bonten, J. I. Ko, K. S. Kim, G. J. Suh, W. Y. Kwon, K. Kim, J. H. Shin, O. T. Ranzani, E. Prina, R. Menendez, A. Ceccato, R. Mendez, C. Cilloniz, A. Gabarrus, M. Ferrer, A. Torres, A. Urbano, L. A. Zhang, D. Swigon, F. Pike, R. S. Parker, G. Clermont, C. Scheer, S. O. Kuhn, A. Modler, M. Vollmer, C. Fuchs, K. Hahnenkamp, S. Rehberg, M. Gründling, A. Taggu, N. Darang, N. Öveges, I. László, K. Tánczos, M. Németh, G. Lebák, B. Tudor, D. Érces, J. Kaszaki, W. Huber, D. Trásy, Z. Molnár, G. Ferrara, V. S. Kanoore Edul, H. S. Canales, E. Martins, C. Canullán, G. Murias, M. O. Pozo, J. F. Caminos Eguillor, M. G. Buscetti, C. Ince, A. Dubin, H. D. Aya, A. Rhodes, N. Fletcher, R. M. Grounds, M. Cecconi, M. Jacquet-Lagrèze, M. Riche, R. Schweizer, P. Portran, W. Fornier, M. Lilot, J. Neidecker, J. L. Fellahi, A. Escoresca-Ortega, A. Gutiérrez-Pizarraya, L. Charris-Castro, Y. Corcia-Palomo, E. Fernandez-Delgado, J. Garnacho-Montero, C. Roger, L. Muller, L. Elotmani, J. Lipman, J. Y. Lefrant, J. A. Roberts, R. Muñoz-Bermúdez, M. Samper, C. Climent, F. Vasco, V. Sara, S. Luque, N. Campillo, S. Grau Cerrato, J. R. Masclans, F. Alvarez-Lerma, S. Carvalho Brugger, G. Jimenez Jimenez, M. Miralbés Torner, J. Trujillano Cabello, B. Balsera Garrido, X. Nuvials Casals, F. Barcenilla Gaite, M. Vallverdú Vidal, M. Palomar Martínez, V. Gusarov, D. Shilkin, M. Dementienko, E. Nesterova, N. Lashenkova, A. Kuzovlev, M. Zamyatin, A. Demoule, S. Carreira, S. Lavault, O. Palancca, E. Morawiec, J. Mayaux, I. Arnulf, T. Similowski, B. S. Rasmussen, R. G. Maltesen, M. Hanifa, S. Pedersen, S. R. Kristensen, R. Wimmer, M. Panigada, G. Li Bassi, T. Kolobow, A. Zanella, M. Cressoni, L. Berra, V. Parrini, H. Kandil, G. Salati, S. Livigni, A. Amatu, A. Andreotti, F. Tagliaferri, G. Moise, G. Mercurio, A. Costa, A. Vezzani, S. Lindau, J. Babel, M. Cavana, D. Consonni, A. Pesenti, L. Gattinoni, for the GRAVITY-VAP TRIAL NETWORK, P. Mansouri, F. Zand, L. Zahed, F. Dehghanrad, M. Bahrani, M. Ghorbani, B. Cambiaghi, O. Moerer, T. Mauri, N. Kunze-Szikszay, C. Ritter, M. Quintel, L. M. Vilander, M. A. Kaunisto, S. T. Vaara, V. Pettilä, FINNAKI Study Group, J. L. G. Haitsma Mulier, S. Rozemeijer, A. M. E. Spoelstra-de Man, P. E. Elbers, P. R. Tuinman, M. C. de Waard, H. M. Oudemans-van Straaten, A. M. A. Liberatore, R. B. Souza, A. M. C. R. P. F. Martins, J. C. F. Vieira, I. H. J. Koh, M. Galindo Martínez, R. Jiménez Sánchez, L. Martínez Gascón, M. D. Rodríguez Mulero, A. Ortín Freire, A. Ojados Muñoz, S. Rebollo Acebes, Á. Fernández Martínez, S. Moreno Aliaga, L. Herrera Para, J. Murcia Payá, F. Rodríguez Mulero, P. Guerci, Y. Ince, P. Heeman, B. Ergin, Z. Uz, M. Massey, R. Papatella, E. Bulent, F. Toraman, E. R. Longbottom, H. D. Torrance, H. C. Owen, C. J. Hinds, R. M. Pearse, M. J. O’Dywer, Z. Trogrlic, M. van der Jagt, H. Lingsma, H. H. Ponssen, J. F. Schoonderbeek, F. Schreiner, S. J. Verbrugge, S. Duran, T. van Achterberg, J. Bakker, D. A. M. P. J. Gommers, E. Ista, A. Krajčová, P. Waldauf, F. Duška, A. Shah, N. Roy, S. McKechnie, C. Doree, S. Fisher, S. J. Stanworth, J. F. Jensen, D. Overgaard, M. H. Bestle, D. F. Christensen, I. Egerod, The RAPIT Group, A. Pivkina, I. Zhivotneva, N. Pasko, A. Alklit, R. L. Hansen, H. Knudsen, L. B. Grode, The RAPIT group, M. Hravnak, L. Chen, A. Dubrawski, M. R. Pinsky, S. M. Parry, L. D. Knight, B. C. Connolly, C. E. Baldwin, Z. A. Puthucheary, L. Denehy, N. Hart, P. E. Morris, J. Mortimore, C. L. Granger, H. I. Jensen, R. Piers, B. Van den Bulcke, J. Malmgren, V. Metaxa, A. K. Reyners, M. Darmon, K. Rusinova, D. Talmor, A. P. Meert, L. Cancelliere, L. Zubek, P. Maia, A. Michalsen, J. Decruyenaere, E. Kompanje, S. Vanheule, E. Azoulay, S. Vansteelandt, D. Benoit, C. Ryan, D. Dawson, J. Ball, K. Noone, B. Aisling, S. Prudden, A. Ntantana, D. Matamis, S. Savvidou, M. Giannakou, M. Gouva, G. Nakos, V. Koulouras, J. Aron, G. Lumley, D. Milliken, K. Dhadwal, B. A. McGrath, S. J. Lynch, B. Bovento, G. Sharpe, E. Grainger, S. Pieri-Davies, S. Wallace, B. McGrath, M. Jung, J. Cho, H. Park, G. Suh, O. Kousha, J. Paddle, L. Gamrin Gripenberg, M. Sundström Rehal, J. Wernerman, O. Rooyackers, H. J. de Grooth, W. P. Choo, A. M. Spoelstra-de Man, E. L. Swart, L. Talan, G. Güven, N. D. Altıntas, M. Padar, G. Uusvel, L. Starkopf, J. Starkopf, A. Reintam Blaser, M. S. Kalaiselvan, A. S. Arunkumar, M. K. Renuka, R. L. Shivkumar, M. Volbeda, D. ten Kate, M. Hoekstra, J. M. van der Maaten, M. W. Nijsten, A. Komaromi, Å. Norberg, M. Smedberg, M. Mori, L. Pettersson, M. Theodorakopoulou, T. Christodoulopoulou, A. Diamantakis, F. Frantzeskaki, M. Kontogiorgi, E. Chrysanthopoulou, M. Lygnos, C. Diakaki, A. Armaganidis, K. Gundogan, E. Dogan, R. Coskun, S. Muhtaroglu, M. Sungur, T. Ziegler, M. Guven, A. Kleyman, W. Khaliq, D. Andreas, M. Singer, R. Meierhans, R. Schuepbach, I. De Brito-Ashurst, G. Sabetian, R. Nikandish, F. Hagar, M. Masjedi, B. Maghsudi, A. Vazin, E. Asadpour, K. C. Kao, L. C. Chiu, C. Y. Hung, C. H. Chang, S. H. Li, H. C. Hu, S. El Maraghi, M. Ali, D. Rageb, M. Helmy, J. Marin-Corral, C. Vilà, A. Vàzquez, I. Martín-Loeches, E. Díaz, J. C. Yébenes, A. Rodriguez, F. Álvarez-Lerma, H1N1 SEMICYUC/GETGAG Working Group, N. Varga, A. Cortina-Gutiérrez, L. Dono, M. Martínez-Martínez, C. Maldonado, E. Papiol, M. Pérez-Carrasco, R. Ferrer, K. Nweze, B. Morton, I. Welters, M. Houard, B. Voisin, G. Ledoux, S. Six, E. Jaillette, S. Nseir, S. Romdhani, R. Bouneb, D. Loghmari, N. Ben Aicha, J. Ayachi, K. Meddeb, I. Chouchène, A. Khedher, M. Boussarsar, K. S. Chan, W. L. Yu, J. Nolla, L. Vidaur, J. Bonastre, B. Suberbiola, J. E. Guerrero, H1N1 SEMICYUC/GETGAG working group, N. Ramon Coll, G. Jiménez Jiménez, J. Codina Calero, M. García, M. C. de la Torre, E. Vendrell, E. Palomera, E. Güell, M. Serra-Prat, J. F. Bermejo-Martín, J. Almirall, E. Tomas, A. Escoval, F. Froe, M. H. Vitoria Pereira, N. Velez, E. Viegas, E. Filipe, C. Groves, M. Reay, A. Ballin, F. Facchin, G. Sartori, F. Zarantonello, E. Campello, C. M. Radu, S. Rossi, C. Ori, P. Simioni, N. Umei, I. Shingo, A. C. Santos, C. Candeias, I. Moniz, R. Marçal, Z. Costa e Silva, J. M. Ribeiro, J. F. Georger, J. P. Ponthus, M. Tchir, V. Amilien, M. Ayoub, E. Barsam, G. Martucci, G. Panarello, F. Tuzzolino, G. Capitanio, V. Ferrazza, T. Carollo, L. Giovanni, A. Arcadipane, M. López Sánchez, M. A. González-Gay, F. J. Llorca Díaz, M. I. Rubio López, E. Zogheib, L. Villeret, J. Nader, M. Bernasinski, P. Besserve, T. Caus, H. Dupont, P. Morimont, S. Habran, R. Hubert, T. Desaive, F. Blaffart, N. Janssen, J. Guiot, A. Pironet, P. Dauby, B. Lambermont, T. Pettenuzzo, G. Citton, C. Kirakli, O. Ediboglu, S. Ataman, M. Yarici, F. Tuksavul, S. Keating, A. Gibson, M. Gilles, M. Dunn, G. Price, N. Young, P. Remeta, P. Bishop, M. D. Fernández Zamora, J. Muñoz-Bono, E. Curiel-Balsera, E. Aguilar-Alonso, R. Hinojosa, A. Gordillo-Brenes, J. A. Arboleda-Sánchez, ARIAM-CARDIAC SURGERY PROJECT AUTHORS, I. Skorniakov, D. Vikulova, C. Whiteley, O. Shaikh, A. Jones, M. Ostermann, L. Forni, M. Scott, J. Sahatjian, W. Linde-Zwirble, D. Hansell, P. Laoveeravat, N. Srisawat, M. Kongwibulwut, S. Peerapornrattana, N. Suwachittanont, T. O. Wirotwan, P. Chatkaew, P. Saeyub, K. Latthaprecha, K. Tiranathanagul, S. Eiam-ong, J. A. Kellum, R. E. Berthelsen, A. Perner, A. E. K. Jensen, J. U. Jensen, D. J. Gebhard, J. Price, C. E. Kennedy, A. Akcan-Arikan, Y. R. Kang, M. N. Nakamae, K. Hamed, M. M. Khaled, R. Aly Soliman, M. Sherif Mokhtar, G. Seller-Pérez, D. Arias-Verdú, E. Llopar-Valdor, I. De-Diós-Chacón, G. Quesada-García, M. E. Herrera-Gutierrez, R. Hafes, G. Carroll, P. Doherty, C. Wright, I. G. Guerra Vera, M. Ralston, M. L. Gemmell, A. MacKay, E. Black, R. I. Docking, R. Appleton, M. R. Ralston, L. Gemmell, A. Mackay, J. G. Röttgering, P. W. G. Elbers, N. Mejeni, J. Nsiala, A. Kilembe, P. Akilimali, G. Thomas, A. E. Andersson, A. M. Fagerdahl, V. Knudsen, P-INFECT, A. Ben Cheikh, Y. Hamdaoui, A. Guiga, N. Fraj, N. Sma, I. Chouchene, N. Bouafia, A. Amirian, B. Ziaian, C. Fleischmann, D. O. Thomas-Rueddel, A. Schettler, D. Schwarzkopf, A. Stacke, K. Reinhart, A. Martins, P. Sousa, G. Snell, R. Matsa, T. T. S. Paary, A. M. Cavalheiro, L. L. Rocha, C. S. Vallone, A. Tonilo, M. D. S. Lobato, D. T. Malheiro, G. Sussumo, N. M. Lucino, V. D. Rosenthal, A. Sanaei Dashti, A. Yousefipour, J. R. Goodall, M. Williamson, E. Tant, N. Thomas, C. Balci, C. Gonen, E. Haftacı, H. Gurarda, E. Karaca, B. Paldusová, I. Zýková, D. Šímová, S. Houston, L. D’Antona, J. Lloyd, V. Garnelo-Rey, M. Sosic, V. Sotosek-Tokmazic, J. Kuharic, I. Antoncic, S. Dunatov, A. Sustic, C. T. Chong, M. Sim, T. Lyovarin, F. M. Acosta Díaz, S. Narbona Galdó, M. Muñoz Garach, O. Moreno Romero, A. M. Pérez Bailón, A. Carranza Pinel, M. Colmenero, A. Gritsan, A. Gazenkampf, E. Korchagin, N. Dovbish, R. M. Lee, M. P. P. Lim, B. C. L. Lim, J. J. See, R. Assis, F. Filipe, N. Lopes, L. Pessoa, T. Pereira, N. Catorze, M. S. Aydogan, C. Aldasoro, P. Marchio, A. Jorda, M. D. Mauricio, S. Guerra-Ojeda, M. Gimeno-Raga, M. Colque-Cano, A. Bertomeu-Artecero, M. Aldasoro, S. L. Valles, D. Tonon, T. Triglia, J. C. Martin, M. C. Alessi, N. Bruder, P. Garrigue, L. Velly, S. Spina, V. Scaravilli, C. Marzorati, E. Colombo, D. Savo, A. Vargiolu, G. Cavenaghi, G. Citerio, A. H. V. Andrade, P. Bulgarelli, J. A. P. Araujo, V. Gonzalez, V. A. Souza, C. Massant, C. A. C. Abreu Filho, R. A. Morbeck, L. E. Burgo, R. van Groenendael, L. T. van Eijk, G. P. Leijte, B. Koeneman, M. Kox, P. Pickkers, A. García-de la Torre, M. de la Torre-Prados, A. Fernández-Porcel, C. Rueda-Molina, P. Nuevo-Ortega, T. Tsvetanova-Spasova, E. Cámara-Sola, A. García-Alcántara, L. Salido-Díaz, X. Liao, T. Feng, J. Zhang, X. Cao, Q. Wu, Z. Xie, H. Li, Y. Kang, M. S. Winkler, A. Nierhaus, E. Mudersbach, A. Bauer, L. Robbe, C. Zahrte, E. Schwedhelm, S. Kluge, C. Zöllner, E. Mitsi, S. H. Pennington, J. Reine, A. D. Wright, R. Parker, I. D. Welters, J. D. Blakey, G. Rajam, E. W. Ades, D. M. Ferreira, D. Wang, A. Kadioglu, S. B. Gordon, R. Koch, J. Rahamat-Langedoen, J. Schloesser, M. de Jonge, J. Bringue, R. Guillamat-Prats, E. Torrents, M. L. Martinez, M. Camprubí-Rimblas, L. Blanch, S. Y. Park, Y. B. Park, D. K. Song, S. Shrestha, S. H. Park, Y. Koh, M. J. Park, C. W. Hong, O. Lesur, D. Coquerel, X. Sainsily, J. Cote, T. Söllradl, A. Murza, L. Dumont, R. Dumaine, M. Grandbois, P. Sarret, E. Marsault, D. Salvail, M. Auger-Messier, F. Chagnon, Apelin Group, M. P. Lauretta, E. Greco, A. Dyson, S. Preau, M. Ambler, A. Sigurta, S. Saeed, L. Topcu Sarıca, N. Zibandeh, D. Genc, F. Gul, T. Akkoc, E. Kombak, L. Cinel, I. Cinel, S. J. Pollen, N. Arulkumaran, G. Warnes, D. J. Pennington, K. Brohi, M. J. O’Dwyer, H. Y. Kim, S. Na, J. Kim, Y. F. Chang, A. Chao, P. Y. Shih, C. T. Lee, Y. C. Yeh, L. W. Chen, M. Adriaanse, W. Rietdijk, S. Funcke, S. Sauerlaender, B. Saugel, H. Pinnschmidt, D. A. Reuter, R. Nitzschke, S. Perbet, C. Biboulet, A. Lenoire, D. Bourdeaux, B. Pereira, B. Plaud, J. E. Bazin, V. Sautou, A. Mebazaa, J. M. Constantin, M. Legrand, Y. Boyko, P. Jennum, M. Nikolic, H. Oerding, R. Holst, P. Toft, H. K. Nedergaard, T. Haberlandt, S. Park, S. Kim, Y. J. Cho, Y. J. Lim, A. Chan, S. Tang, S. L. Nunes, S. Forsberg, H. Blomqvist, L. Berggren, M. Sörberg, T. Sarapohja, C. J. Wickerts, J. G. M. Hofhuis, L. Rose, B. Blackwood, E. Akerman, J. Mcgaughey, M. Fossum, H. Foss, E. Georgiou, H. J. Graff, M. Kalafati, R. Sperlinga, A. Schafer, A. G. Wojnicka, P. E. Spronk, F. Khalili, R. Afshari, H. Haddad Khodaei, S. Javadpour, P. Petramfar, S. Nasimi, H. Tabei, A. Gunther, J. O. Hansen, P. Sackey, H. Storm, J. Bernhardsson, Ø. Sundin, A. Bjärtå, A. Bienert, P. Smuszkiewicz, P. Wiczling, K. Przybylowski, A. Borsuk, I. Trojanowska, J. Matysiak, Z. Kokot, M. Paterska, E. Grzeskowiak, A. Messina, E. Bonicolini, D. Colombo, G. Moro, S. Romagnoli, A. R. De Gaudio, F. Della Corte, S. M. Romano, J. A. Silversides, E. Major, E. E. Mann, A. J. Ferguson, D. F. Mcauley, J. C. Marshall, J. A. Diaz-Rodriguez, R. Silva-Medina, E. Gomez-Sandoval, N. Gomez-Gonzalez, R. Soriano-Orozco, P. L. Gonzalez-Carrillo, M. Hernández-Flores, K. Pilarczyk, J. Lubarksi, D. Wendt, F. Dusse, J. Günter, B. Huschens, E. Demircioglu, H. Jakob, A. Palmaccio, A. M. Dell’Anna, D. L. Grieco, F. Torrini, C. Iaquaniello, F. Bongiovanni, M. Antonelli, L. Toscani, D. Antonakaki, D. Bastoni, M. Jozwiak, F. Depret, J. L. Teboul, J. Alphonsine, C. Lai, C. Richard, X. Monnet, G. Demeter, I. Kertmegi, A. Hasanin, A. Lotfy, A. El-adawy, H. Nassar, S. Mahmoud, A. Abougabal, A. Mukhtar, F. Quinty, S. Habchi, A. Luzi, E. Antok, G. Hernandez, B. Lara, L. Enberg, M. Ortega, P. Leon, C. Kripper, P. Aguilera, E. Kattan, M. Lehmann, S. Sakka, B. Bein, R. M. Schmid, J. Preti, J. Creteur, A. Herpain, J. Marc, F. Trojette, S. Bar, L. Kontar, D. Titeca, J. Richecoeur, B. Gelee, N. Verrier, R. Mercier, E. Lorne, J. Maizel, M. Slama, M. E. Abdelfattah, A. Eladawy, M. A. Ali Elsayed, A. Pedraza Montenegro, E. Monares Zepeda, J. Franco Granillo, J. S. Aguirre Sánchez, G. Camarena Alejo, A. Rugerio Cabrera, A. A. Tanaka Montoya, C. Lee, F. Hatib, M. Cannesson, P. Theerawit, T. Morasert, Y. Sutherasan, G. Zani, S. Mescolini, M. Diamanti, R. Righetti, A. Scaramuzza, M. Papetti, M. Terenzoni, C. Gecele, M. Fusari, K. A. Hakim, A. Chaari, M. Ismail, A. H. Elsaka, T. M. Mahmoud, K. Bousselmi, V. Kauts, W. F. Casey, S. D. Hutchings, D. Naumann, J. Wendon, S. Watts, E. Kirkman, Z. Jian, S. Buddi, J. Settels, P. Bertini, F. Guarracino, C. Trepte, P. Richter, S. A. Haas, V. Eichhorn, J. C. Kubitz, M. S. Soliman, W. I. Hamimy, A. Z. Fouad, A. M. Mukhtar, M. Charlton, L. Tonks, L. Mclelland, T. J. Coats, J. P. Thompson, M. R. Sims, D. Williams, D. Z. Roushdy, R. A. Soliman, R. A. Nahas, M. Y. Arafa, W. T. Hung, C. C. Chiang, W. C. Huang, K. C. Lin, S. C. Lin, C. C. Cheng, P. L. Kang, S. R. Wann, G. Y. Mar, C. P. Liu, M. Lopez Carranza, H. Sancho Fernandez, J. A. Sanchez Roman, F. Lucena, A. Campanario Garcia, A. Loza Vazquez, A. Lesmes Serrano, ARIAM-SEMICYUC Registry Investigators, L. Sayagues Moreira, R. Vidal-Perez, U. Anido Herranz, J. M. Garcia Acuna, C. Pena Gil, J. L. Garcia Allut, P. Rascado Sedes, C. Martin Lopez, E. Saborido Paz, C. Galban Rodriguez, J. R. Gonzalez-Juanatey, A. Vallejo-Baez, M. V. de la Torre-Prados, ARIAM Group, R. Marharaj, K. Gervasio, M. Bottiroli, M. Mondino, D. De Caria, A. Calini, E. Montrasio, F. Milazzo, M. P. Gagliardone, A. Vallejo-Báez, ARIAM group, U. Anido, M. Cheikh-Bouhlel, M. P. R. D. L. Dela Cruz, J. M. Bernardo, F. Galfo, A. Marino, C. C. Chao, P. Hou, C. C. Hung, C. H. Chiang, Y. J. Liou, S. M. Hung, Y. S. Lin, F. Y. Kuo, K. R. Chiou, C. J. Chen, L. S. Yan, C. Y. Liu, H. H. Wang, H. L. Chen, C. K. Ho, S. Grewal, S. Gopal, C. Corbett, A. Wilson, J. Capps, W. Ayoub, A. Lomas, S. Ghani, J. Moore, D. Atkinson, M. Sharman, W. Swinnen, J. Pauwels, K. Mignolet, E. Pannier, A. Koch, T. Sarens, W. Temmerman, A. M. Elmenshawy, A. M. Fayed, M. Elboriuny, E. Hamdy, E. Zakaria, A. C. Falk, A. Petosic, K. Olafsen, H. Wøien, H. Flaatten, K. Sunde, J. J. Cáceres Agra, J. L. Santana Cabrera, J. D. Martín Santana, L. Melián Alzola, H. Rodríguez Pérez, T. Castro Pires, H. Calderón, A. Pereira, S. Castro, C. Granja, I. Norkiene, I. Urbanaviciute, G. Kezyte, D. Ringaitiene, T. Jovaisa, G. Vogel, U. B. Johansson, A. Sandgren, C. Svensen, E. Joelsson-Alm, M. A. Leite, L. D. Murbach, E. F. Osaku, C. R. L. M. Costa, M. Pelenz, N. M. Neitzke, M. M. Moraes, J. L. Jaskowiak, M. M. M. Silva, R. S. Zaponi, L. R. L. Abentroth, S. M. Ogasawara, A. C. Jorge, P. A. D. Duarte, J. Barreto, S. T. Duarte, S. Taba, D. Miglioranza, D. P. Gund, C. F. Lordani, H. Vollmer, M. Gager, C. Waldmann, A. T. Mazzeo, R. Tesio, C. Filippini, M. E. Vallero, C. Giolitti, S. Caccia, M. Medugno, T. Tenaglia, R. Rosato, I. Mastromauro, L. Brazzi, P. P. Terragni, R. Urbino, V. Fanelli, V. M. Ranieri, L. Mascia, J. Ballantyne, L. Paton, P. Perez-Teran, O. Roca, J. C. Ruiz-Rodriguez, A. Zapatero, J. Serra, S. Bianzina, P. Cornara, G. Rodi, G. Tavazzi, M. Pozzi, G. A. Iotti, F. Mojoli, A. Braschi, A. Vishnu, D. Buche, R. Pande, D. L. J. Moolenaar, F. Bakhshi-Raiez, D. A. Dongelmans, N. F. de Keizer, D. W. de Lange, I. Fuentes Fernández, D. Martínez Baño, J. L. Buendía Moreno, R. Jara Rubio, J. Scott, D. Phelan, D. Morely, J. O’Flynn, P. Stapleton, M. Lynch, B. Marsh, E. Carton, C. O’Loughlin, K. C. Cheng, M. I. Sung, M. O. Elghonemi, M. H. Saleh, T. S. Meyhoff, M. Krag, P. B. Hjortrup, M. H. Møller, T. Öhman, T. Sigmundsson, E. Redondo, M. Hallbäck, F. Suarez-Sipmann, H. Björne, C. Hällsjö Sander, KARISMA, D. Chiumello, C. Chiurazzi, M. Brioni, I. Algieri, M. Guanziroli, G. Vergani, T. Tonetti, I. Tomic, A. Colombo, F. Crimella, E. Carlesso, V. Gasparovic, R. El-Sherif, M. Abd Al-Basser, A. Raafat, A. El-Sherif, L. R. A. Schouten, O. L. Cremer, D. S. Y. Ong, G. Amoruso, G. Cinnella, L. D. J. Bos, P. Schmidle, M. Findeisen, P. Hoppmann, J. Jaitner, F. Brettner, T. Lahmer, EXODUS-investigators, G. Rajagopalan, V. Bansal, R. Frank, R. Hinds, J. Levitt, United States Critical Illness and Injury Trials Group/LIPS-B investigators, S. Siddiqui, SICM NICER Group, J. P. Gilbert, K. Sim, C. H. Wang, I. J. Li, W. R. Tang, P. Persona, A. De Cassai, M. Franco, A. Goffi, B. Llorente Ruiz, J. Lujan Varas, R. Molina Montero, C. Pintado Delgado, O. Navarrete, M. Vazquez Mezquita, E. Alonso Peces, M. A. M. Nakamura, L. A. Hajjar, F. R. B. G. Galas, T. A. Ortiz, M. B. P. Amato, L. Bitker, N. Costes, D. Le Bars, F. Lavenne, D. Mojgan, J. C. Richard, D. Massari, M. Gotti, P. Cadringher, A. Zerman, M. Türkoğlu, G. Arık, F. Yıldırım, Z. Güllü, I. Kara, N. Boyacı, B. Basarık Aydoğan, Ü. Gaygısız, K. Gönderen, G. Aygencel, M. Aydoğdu, Z. Ülger, G. Gürsel, J. Riera, C. Maldonado Toral, C. Mazo, M. Martínez, J. Baldirà, L. Lagunes, A. Roman, M. Deu, J. Rello, D. J. Levine, R. M. Mohus, Å. Askim, J. Paulsen, A. Mehl, A. T. Dewan, J. K. Damås, E. Solligård, B. O. Åsvold, Mid-Norway Sepsis Research Center, A. DeWan, O. Aktepe, A. Kara, H. Yeter, A. Topeli, M. Norrenberg, M. Devroey, H. Khader, J. C. Preiser, Z. Tang, C. Qiu, L. Tong, C. Cai, O. Apostolopoulou, J. Y. Moon, M. R. Park, I. S. Kwon, G. R. Chon, J. Y. Ahn, S. J. Kwon, Y. J. Chang, J. Y. Lee, S. Y. Yoon, J. W. Lee, The Korean Chungcheong Critical Care Research Group, M. Kostalas, J. Mckinlay, G. Kooner, G. Dudas, A. Horton, C. Kerr, N. Karanjia, B. Creagh-Brown, N. D. Altintas, S. Izdes, O. Keremoglu, A. Alkan, S. Neselioglu, O. Erel, N. Tardif, T. Gustafsson, K. N. MacEachern, M. Traille, I. Bromberg, S. E. Lapinsky, M. J. Moore, J. L. García-Garmendia, F. Villarrasa-Clemente, F. Maroto-Monserrat, O. Rufo-Tejeiro, V. Jorge-Amigo, M. Sánchez-Santamaría, C. Colón-Pallarés, A. Barrero-Almodóvar, S. Gallego-Lara, C. T. Anthon, R. B. Müller, N. Haase, K. Møller, J. Wetterslev, M. Nakanishi, A. Kuriyama, T. Fukuoka, M. A. Abd el Halim, M. H. Elsaid hafez, A. M. Moktar, H. M. Elazizy, K. Abdel Hakim, M. Elbahr, T. Mahmoud, E. Khalil, W. Casey, S. H. Zaky, A. Rizk, R. Ahmed, G. A. Ospina-Tascón, A. F. Garcia Marin, G. J. Echeverry, W. F. Bermudez, H. J. Madriñan-Navia, J. D. Valencia, E. Quiñonez, A. Marulanda, C. A. Arango-Dávila, A. Bruhn, D. De Backer, D. Orbegozo Cortes, F. Su, J. L. Vincent, L. Tullo, L. Mirabella, P. Di Molfetta, M. Dambrosio, C. Villavicencio Lujan, J. Leache irigoyen, M. Cartanya ferré, R. Carbonell García, M. Ahmed, M. El Ayashi, E. Ayman, M. Salem, S. Fathy, A. Zaghlol, M. F. Aguilar Arzapalo, Å. Valsø, T. Rustøen, I. Schou-Bredal, L. Skogstad, K. Tøien, C. Padilla, Y. Palmeiro, W. Egbaria, R. Kigli, B. Maertens, K. Blot, S. Blot, E. Santana-Santos, E. R. dos Santos, R. E. D. L. Ferretti-Rebustini, R. D. C. C. D. O. dos Santos, R. G. S. Verardino, L. A. Bortolotto, A. M. Doyle, I. Naldrett, J. Tillman, S. Price, P. Pearson, J. Greaves, D. Goodall, A. Berry, A. Richardson, G. O. Odundo, P. Omengo, P. Obonyo, N. M. Chanzu, R. Kleinpell, S. J. Sarris, P. Nedved, M. Heitschmidt, H. Ben-Ghezala, S. Snouda, S. Djobbi, N. K. J. Adhikari, D. Leasa, D. Fergusson, D. A. Mckim, J. Weblin, D. McWilliams, F. Doesburg, F. Cnossen, W. Dieperink, W. Bult, M. W. N. Nijsten, G. A. Galvez-Blanco, C. I. Olvera Guzman, J. Santos Stroud, R. Thomson, M. Llaurado-Serra, A. Lobo-Civico, M. Pi-Guerrero, I. Blanco-Sanchez, A. Piñol-Tena, C. Paños-Espinosa, Y. Alabart-Segura, B. Coloma-Gomez, A. Fernandez-Blanco, F. Braga-Dias, M. Treso-Geira, A. Valeiras-Valero, L. Martinez-Reyes, A. Sandiumenge, M. F. Jimenez-Herrera, CAPCRI Study, R. Prada, P. Juárez, R. Argandoña, J. J. Díaz, C. Sánchez Ramirez, P. Saavedra, S. Ruiz Santana, O. Obukhova, S. Kashiya, I. A. Kurmukov, A. M. Pronina, P. Simeone, L. Puybasset, G. Auzias, O. Coulon, B. Lesimple, G. Torkomian, A. Bartkowska-Sniatkowska, O. Szerkus, D. Siluk, J. Bartkowiak-Wieczorek, J. Rosada-Kurasinska, J. Warzybok, R. Kaliszan, C. Hernandez Caballero, S. Roberts, G. Isgro, D. Hall, G. Guillaume, O. Passouant, F. Dumas, W. Bougouin, B. Champigneulle, M. Arnaout, J. Chelly, J. D. Chiche, O. Varenne, J. P. Mira, E. Marijon, A. Cariou, M. Beerepoot, H. R. Touw, K. Parlevliet, C. Boer, P. W. Elbers, Á. J. Roldán Reina, Y. Corcia Palomo, R. Martín Bermúdez, L. Martín Villén, I. Palacios García, J. R. Naranjo Izurieta, J. B. Pérez Bernal, F. J. Jiménez Jiménez, Cardiac Arrest Group HUVR, F. Cota-Delgado, T. Kaneko, H. Tanaka, M. Kamikawa, R. Karashima, S. Iwashita, H. Irie, S. Kasaoka, O. Arola, R. Laitio, A. Saraste, J. Airaksinen, M. Pietilä, M. Hynninen, J. Wennervirta, M. Bäcklund, E. Ylikoski, P. Silvasti, E. Nukarinen, J. Grönlund, V. P. Harjola, J. Niiranen, K. Korpi, M. Varpula, R. O. Roine, T. Laitio, for the Xe-HYPOTHECA study group, S. Salah, B. G. Hassen, A. Mohamed Fehmi, Y. C. Hsu, J. Barea-Mendoza, C. García-Fuentes, M. Castillo-Jaramillo, H. Dominguez-Aguado, R. Viejo-Moreno, L. Terceros-Almanza, S. Bermejo Aznárez, C. Mudarra-Reche, W. Xu, M. Chico-Fernández, J. C. Montejo-González, K. Crewdson, M. Thomas, M. Merghani, L. Fenner, P. Morgan, D. Lockey, E. J. van Lieshout, B. Oomen, J. M. Binnekade, R. J. de Haan, N. P. Juffermans, M. B. Vroom, R. Algarte, L. Martínez, B. Sánchez, I. Romero, F. Martínez, S. Quintana, J. Trenado, O. Sheikh, D. Pogson, R. Clinton, F. Riccio, A. Arthur, L. Young, A. Sinclair, D. Markopoulou, K. Venetsanou, L. Filippou, E. Salla, S. Stratouli, I. Alamanos, A. H. Guirgis, R. Gutiérrez Rodriguez, M. J. Furones Lorente, I. Macias Guarasa, A. Ukere, S. Meisner, G. Greiwe, B. Opitz, D. Benten, B. Nashan, L. Fischer, C. J. C. Trepte, C. R. Behem, B. Ana, A. Vazir, D. Gibson, M. R. Hadavi, M. Riahi alam, M. R. Sasani, N. Parenti, F. Agrusta, C. Palazzi, B. Pifferi, R. Sganzerla, F. Tagliazucchi, A. Luciani, M. Möller, J. Müller-Engelmann, G. Montag, P. Adams, C. Lange, J. Neuzner, R. Gradaus, K. H. Wodack, F. Thürk, A. D. Waldmann, M. F. Grässler, S. Nishimoto, S. H. Böhm, E. Kaniusas, C. J. Trepte, M. Wallin, F. Suarez Sipman, A. Oldner, L. Colinas, R. Vicho, M. Serna, R. Cuena, A. Canabal, ECOCRITIC group, M. Etman, M. El Bahr, A. El Sakka, A. Arali, O. Bond, P. De Santis, E. Iesu, F. Franchi, S. Scolletta, F. S. Taccone, Z. Marutyan, L. Hamidova, A. Shakotko, V. Movsisyan, I. Uysupova, A. Evdokimov, S. Petrikov, F. J. Redondo Calvo, N. Bejarano, V. Baladron, R. Villazala, J. Redondo, D. Padilla, P. Villarejo, C. Gomez-Gonzalez, S. Mas-Font, A. Puppo-Moreno, M. Herrera-Gutierrez, M. Garcia-Garcia, S. Aldunate-Calvo, NEFROCON Investigators, E. P. Plata-Menchaca, X. L. Pérez-Fernández, M. Estruch, A. Betbese-Roig, P. Cárdenas Campos, M. Rojas Lora, N. D. Toapanta Gaibor, R. S. Contreras Medina, V. D. Gumucio Sanguino, E. J. Casanova, J. Sabater Riera, SIRAKI group, K. Kritmetapak, S. Peerapornratana, P. Kittiskulnam, T. Dissayabutra, P. Susantithapong, K. Praditpornsilpa, K. Tungsanga, S. Eiam-Ong, T. Winkelmann, T. Busch, J. Meixensberger, S. Bercker, E. M. Flores Cabeza, M. Sánchez Sánchez, N. Cáceres Giménez, C. Gutierrez Melón, E. Herrero de Lucas, P. Millán Estañ, M. Hernández Bernal, A. Garcia de Lorenzo y Mateos, P. A. C. Specht, M. Balik, M. Zakharchenko, F. Los, H. Brodska, C. de Tymowski, P. Augustin, M. Desmard, P. Montravers, S. N. Stapel, R. de Boer, H. M. Oudemans, A. Hollinger, T. Schweingruber, F. Jockers, M. Dickenmann, M. Siegemund, Clinical Intensive Care Research Basel, N. Runciman, L. Alban, C. Turrini, T. Sasso, T. Langer, P. Taccone, C. Marenghi, G. Grasselli, P. Wibart, T. Reginault, M. Garcia, B. Barbrel, A. Benard, C. Bader, F. Vargas, H. N. Bui, G. Hilbert, J. M. Serrano Simón, P. Carmona Sánchez, F. Ruiz Ferrón, M. García de Acilu, J. Marin, V. Antonia, L. Ruano, M. Monica, G. Hong, D. H. Kim, Y. S. Kim, J. S. Park, Y. K. Jee, Z. Yu xiang, W. Jia-xing, W. Xiao dan, N. Wen long, W. Yu, Z. Yan, X. Cheng, T. Kobayashi, Y. Onodera, R. Akimoto, A. Sugiura, H. Suzuki, M. Iwabuchi, M. Nakane, K. Kawamae, P. Carmona Sanchez, M. D. Bautista Rodriguez, M. Rodriguez Delgado, V. Martínez de Pinillos Sánchez, A. Mula Gómez, P. Beuret, C. Fortes, M. Lauer, M. Reboul, J. C. Chakarian, X. Fabre, B. Philippon-Jouve, S. Devillez, M. Clerc, N. Rittayamai, M. Sklar, M. Dres, M. Rauseo, C. Campbell, B. West, D. E. Tullis, M. Okada, N. Ahmad, M. Wood, A. Glossop, J. Higuera Lucas, A. Blandino Ortiz, D. Cabestrero Alonso, R. De Pablo Sánchez, L. Rey González, R. Costa, G. Spinazzola, A. Pizza, G. Ferrone, M. Rossi, G. Conti, H. Ribeiro, J. Alves, M. Sousa, P. Reis, C. S. Socolovsky, R. P. Cauley, J. E. Frankel, A. L. Beam, K. O. Olaniran, F. K. Gibbons, K. B. Christopher, J. Pennington, P. Zolfaghari, H. S. King, H. H. Y. Kong, H. P. Shum, W. W. Yan, C. Kaymak, N. Okumus, A. Sari, B. Erdogdu, S. Aksun, H. Basar, A. Ozcan, N. Ozcan, D. Oztuna, J. A. Malmgren, S. Lundin, K. Torén, M. Eckerström, A. Wallin, A. C. Waldenström, for the Section on Ethics of the ESICM, F. C. Riccio, A. C. P. Antonio, A. F. Leivas, F. Kenji, E. James, S. Jonnada, C. S. Gerrard, N. Jones, J. D. Salciccioli, D. C. Marshall, M. Komorowski, A. Hartley, M. C. Sykes, R. Goodson, J. Shalhoub, J. R. Fernández Villanueva, R. Fernández Garda, A. M. López Lago, E. Rodríguez Ruiz, R. Hernández Vaquero, C. Galbán Rodríguez, E. Varo Pérez, C. Hilasque, I. Oliva, G. Sirgo, M. C. Martin, M. Olona, M. C. Gilavert, M. Bodí, C. Ebm, G. Aggarwal, S. Huddart, N. Quiney, S. M. Fernandes, J. Santos Silva, J. Gouveia, D. Silva, R. Marques, H. Bento, A. Alvarez, Z. Costa Silva, D. Díaz Diaz, M. Villanova Martínez, E. Palencia Herrejon, A. Martinez de la Gandara, G. Gonzalo, M. A. Lopez, P. Ruíz de Gopegui Miguelena, C. I. Bernal Matilla, P. Sánchez Chueca, M. D. C. Rodríguez Longares, R. Ramos Abril, A. L. Ruíz Aguilar, R. Garrido López de Murillas, R. Fernández Fernández, P. Morales Laborías, M. A. Díaz Castellanos, M. E. Morales Laborías, J. Park, S. Woo, T. West, E. Powell, A. Rimmer, C. Orford, J. Williams, P. Ruiz de Gopegui Miguelena, R. S. Bourne, R. Shulman, M. Tomlin, G. H. Mills, M. Borthwick, W. Berry, D. García Huertas, F. Manzano, F. Villagrán-Ramírez, A. Ruiz-Perea, C. Rodríguez-Mejías, F. Santiago-Ruiz, M. Colmenero-Ruiz, C. König, B. Matt, A. Kortgen, C. S. Hartog, A. Wong, C. Balan, G. Barker, S. Tachaboon, J. Paratz, G. Kayambu, R. Boots, R. Vlasenko, E. Gromova, S. Loginov, M. Kiselevskiy, Y. Dolgikova, K. B. Tang, C. M. Chau, K. N. Lam, E. Gil, G. Y. Suh, C. M. Park, C. R. Chung, C. H. Lai, Y. J. Cheng, V. Colella, N. Zarrillo, M. D’Amico, F. Forfori, B. Pezza, T. Laddomada, V. Beltramelli, M. L. Pizzaballa, A. Doronzio, B. Balicco, D. Kiers, W. van der Heijden, J. Gerretsen, Q. de Mast, S. el Messaoudi, G. Rongen, M. Gomes, N. P. Riksen, Y. Kashiwagi, K. Hayashi, Y. Inagaki, S. Fujita, A. Blet, M. Sadoune, J. Lemarié, N. Bihry, R. Bern, E. Polidano, R. Merval, J. M. Launay, B. Lévy, J. L. Samuel, J. Hartmann, S. Harm, and V. Weber
- Subjects
LUNG SAFE investigators and the ESICM study group ,medicine.medical_specialty ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,KARISMA ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,030204 cardiovascular system & hematology ,ARIAM Group ,Critical Care and Intensive Care Medicine ,Meeting Abstracts ,Vascular occlusion ,GRAVITY-VAP TRIAL NETWORK ,03 medical and health sciences ,0302 clinical medicine ,H1N1 SEMICYUC/GETGAG working group ,Xe-HYPOTHECA study group ,Clinical Intensive Care Research Basel ,Healthy volunteers ,Journal Article ,United States Critical Illness and Injury Trials Group/LIPS-B investigators ,Medicine ,ARIAM-CARDIAC SURGERY PROJECT AUTHORS ,GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries) ,RAPIT group ,FINNAKI Study Group ,Cardiac Arrest Group HUVR ,business.industry ,Mid-Norway Sepsis Research Center ,NEFROCON Investigators ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,SIRAKI group ,Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16] ,030208 emergency & critical care medicine ,lcsh:RC86-88.9 ,SICM NICER Group ,LUNG SAFE Investigators and the ESICM Trials Group ,ARIAM-SEMICYUC Registry Investigators ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,CAPCRI Study ,Apelin Group ,Section on Ethics of the ESICM ,Anesthesia ,EXODUS-investigators ,Infrared thermal imaging ,Radiology ,medicine.symptom ,Korean Chungcheong Critical Care Research Group ,ECOCRITIC group ,business ,P-INFECT - Abstract
Contains fulltext : 172380.pdf (Publisher’s version ) (Open Access)
- Published
- 2016
47. O-GlcNAcylation in Cancer Biology: Linking Metabolism and Signaling
- Author
-
Mauricio J. Reginato, Christina M. Ferrer, and Valerie L. Sodi
- Subjects
0301 basic medicine ,Glycosylation ,Carcinogenesis ,mTORC1 ,Biology ,medicine.disease_cause ,Article ,03 medical and health sciences ,Structural Biology ,Neoplasms ,medicine ,Animals ,Humans ,Molecular Biology ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Cancer ,medicine.disease ,Biosynthetic Pathways ,Metabolic pathway ,030104 developmental biology ,Biochemistry ,Cancer cell ,Flux (metabolism) ,Metabolic Networks and Pathways ,Signal Transduction - Abstract
The hexosamine biosynthetic pathway (HBP) is highly dependent on multiple metabolic nutrients including glucose, glutamine, and acetyl-CoA. Increased flux through HBP leads to elevated post-translational addition of β-D-N-acetylglucosamine sugars to nuclear and cytoplasmic proteins. Increased total O-GlcNAcylation is emerging as a general characteristic of cancer cells, and recent studies suggest that O-GlcNAcylation is a central communicator of nutritional status to control key signaling and metabolic pathways that regulate multiple cancer cell phenotypes. This review summarizes our current understanding of changes of O-GlcNAc cycling enzymes in cancer, the role of O-GlcNAcylation in tumorigenesis, and the current challenges in targeting this pathway therapeutically.
- Published
- 2016
48. O-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway
- Author
-
Zachary A. Bacigalupa, Mauricio J. Reginato, David A. Sinclair, Christina M. Ferrer, Tong Y. Lu, and Christos D. Katsetos
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,AMPK ,Cancer Research ,Glycosylation ,deacetylation ,Breast Neoplasms ,Biology ,N-Acetylglucosaminyltransferases ,Molecular oncology ,Article ,Metastasis ,03 medical and health sciences ,Mice ,SIRT1 ,Growth factor receptor ,Sirtuin 1 ,Mice, Inbred NOD ,Cell Line, Tumor ,Genetics ,medicine ,cancer ,metastasis ,Animals ,Humans ,Neoplasm Metastasis ,Protein kinase A ,Molecular Biology ,Transcription factor ,Cell Proliferation ,Forkhead Box Protein M1 ,FOXM1 ,Cancer ,medicine.disease ,invasion ,MEK ,sirtuin ,ERK ,030104 developmental biology ,Cancer cell ,Cancer research ,O-GlcNAc ,OGT ,MCF-7 Cells ,Heterografts ,Female ,metabolism ,hormones, hormone substitutes, and hormone antagonists - Abstract
Tumors utilize aerobic glycolysis to support growth and invasion. However, the molecular mechanisms that link metabolism with invasion are not well understood. The nutrient sensor O-linked-β-N-acetylglucosamine (O-GlcNAc) transferase (OGT) modifies intracellular proteins with N-acetylglucosamine. Cancers display elevated O-GlcNAcylation and suppression of O-GlcNAcylation inhibits cancer invasion and metastasis. Here, we show that the regulation of cancer invasion by OGT is dependent on the NAD+-dependent deacetylase SIRT1. Reducing O-GlcNAcylation elevates SIRT1 levels and activity in an AMPK (AMP-activated protein kinase α)-dependent manner. Reduced O-GlcNAcylation in cancer cells leads to SIRT1-mediated proteasomal degradation of oncogenic transcription factor FOXM1 in an MEK/ERK-dependent manner. SIRT1 is critical for OGT-mediated regulation of FOXM1 ubiquitination and reducing SIRT1 activity reverses OGT-mediated regulation of FOXM1. Moreover, we show that SIRT1 levels are required for OGT-mediated regulation of invasion and metastasis in breast cancer cells. Thus, O-GlcNAcylation is a central component linking metabolism to invasion and metastasis via an SIRT1/ERK/FOXM1 axis.
- Published
- 2016
49. The oleanolic acid derivative, 3-O-succinyl-28-O-benzyl oleanolate, induces apoptosis in B16–F10 melanoma cells via the mitochondrial apoptotic pathway
- Author
-
Marta Medina-O'Donnell, Amalia Pérez-Jiménez, Eva E. Rufino-Palomares, Fernando J. Reyes-Zurita, Juan Peragón, Rosa M. Ferrer-Martín, Samuel Martin-Fonseca, Andrés Parra, José A. Lupiáñez, Francisco Rivas, Andrés García-Granados, Khalida Mokhtari, Pedro P. Medina, Leticia García-Salguero, Antonio Martínez, [Reyes-Zurita, Fernando J.] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, E-18071 Granada, Spain, [Rufino-Palomares, Eva E.] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, E-18071 Granada, Spain, [Perez-Jimenez, Amalia] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, E-18071 Granada, Spain, [Garcia-Salguero, Leticia] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, E-18071 Granada, Spain, [Mokhtari, Khalida] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, E-18071 Granada, Spain, [Medina, Pedro P.] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, E-18071 Granada, Spain, [Lupianez, Jose A.] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, E-18071 Granada, Spain, [Medina-O'Donnell, Marta] Univ Granada, Dept Organ Chem, Fac Sci, E-18071 Granada, Spain, [Martin-Fonseca, Samuel] Univ Granada, Dept Organ Chem, Fac Sci, E-18071 Granada, Spain, [Rivas, Francisco] Univ Granada, Dept Organ Chem, Fac Sci, E-18071 Granada, Spain, [Martinez, Antonio] Univ Granada, Dept Organ Chem, Fac Sci, E-18071 Granada, Spain, [Garcia-Granados, Andres] Univ Granada, Dept Organ Chem, Fac Sci, E-18071 Granada, Spain, [Parra, Andres] Univ Granada, Dept Organ Chem, Fac Sci, E-18071 Granada, Spain, [Ferrer-Martin, Rosa M.] Univ Granada, Dept Cellular Biol, Fac Sci, E-18071 Granada, Spain, [Peragon, Juan] Univ Jaen, Biochem & Mol Biol Sect, Dept Expt Biol, Jaen 23071, Spain, [Mokhtari, Khalida] Mohammed I Univ, Dept Biol, Fac Sci, BP 717, Oujda 60000, Morocco, [Medina, Pedro P.] Univ Granada, Govt Andalusia, Ctr Genom & Oncol Invest GENyO, Pfizer Pharmaceutical, Technol Pk Hlth Sci, Granada 18016, Spain, grant Group BIO from Technology and Innovation Council of the Andalucian regional government, Spanish government, and European Union FEDER funds
- Subjects
0301 basic medicine ,Triterpenoid ,Colon-cancer cells ,General Chemical Engineering ,Cell ,Apoptosis ,Therapeutics ,Growth ,03 medical and health sciences ,chemistry.chemical_compound ,Olive pomace ,Antineoplastic agents ,medicine ,Cytotoxic T cell ,Cytotoxicity ,Melanoma ,Natural triterpene ,Oleanolic acid ,Protein-turnover rates ,Cell growth ,Sparus-aurata ,Depolarization ,General Chemistry ,Betulinic acid ,medicine.disease ,Molecular biology ,Treatment ,White muscle ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,Biochemistry ,Gilthead sea bream ,Maslinic acid ,Adenocarcinoma cells - Abstract
Oleanolic acid (1) is a pentacyclic triterpene present in olive pomace, which is known to induce apoptosis and to have anti-tumor properties; however, high concentrations of this product are necessary to produce cytotoxic effects. The 3-O-succinyl-28-O-benzyl oleanolate derivative (4) presents greater cytotoxicity and apoptosis effects than its natural precursor, oleanolic acid, or its benzyl derivative (2). This study examines the response of B16–F10 melanoma cells to treatment with compound 4, in comparison to 1 and 3. Our studies show that treatment with 4 results in a significant inhibition of cell proliferation in a dose-dependent manner and causes apoptotic cell death. At concentrations inhibiting cell growth by 50% and 80%, compound 4 induces strong G0/G1 cell-cycle arrest, around 72–95% apoptosis, and mitochondrial disturbances confirmed by FACS analysis, which probably involve the activation of the intrinsic apoptotic route. Morphological changes including cell shrinkage, chromatin condensation, and loss of nuclear architecture were also observed. In this report, we demonstrated for the first time that in melanoma cancer cells, compound 4 exerts a significant anti-proliferation effect by inducing the apoptotic process with mitochondrial depolarization. These findings support the role of compound 4 as a new, potential therapeutic tool against aberrant cell proliferation in melanoma., This study was supported by grants Group BIO 157 from the Technology and Innovation Council of the Andalucian regional government and AGL2006-12210-C03-02/ALI, SAF2005-01627, ISCIII-RTICC (RD06/0020/0046) from the Spanish government and European Union FEDER funds.
- Published
- 2016
50. Increased STAT3 phosphorylation on CD27 + B-cells from common variable immunodeficiency disease patients
- Author
-
Guillem Frontera, Catalina Crespí, Jaume Pons, J. M. Ferrer, Núria Matamoros, Nallibe Lanio, Vanesa Cunill, and Antonio Clemente
- Subjects
STAT3 Transcription Factor ,T-Lymphocytes ,Cellular differentiation ,Immunology ,Receptors, Antigen, B-Cell ,Hyperphosphorylation ,Lymphocyte Activation ,Immune system ,medicine ,Humans ,Immunology and Allergy ,CD40 Antigens ,Phosphorylation ,B-cell activating factor ,Receptor ,B-Lymphocytes ,CD40 ,biology ,Interleukins ,Common variable immunodeficiency ,Cell Differentiation ,hemic and immune systems ,medicine.disease ,Molecular biology ,Antibodies, Anti-Idiotypic ,Tumor Necrosis Factor Receptor Superfamily, Member 7 ,Common Variable Immunodeficiency ,biology.protein ,Cancer research - Abstract
Maturation and differentiation of B-cells are driven by T-cells' help through IL-21/STAT3 axis in GC centers or through extrafollicular pathways, in a T-independent manner. B-cell differentiation is defective in common variable immunodeficiency disease (CVID) patients. We investigated if IL-21/STAT3 axis alterations could influence B-cell fate. We activated purified CVID B-cells with surrogate T-dependent (anti-CD40), T-independent (TLR-9 ligand) stimuli or through B-cell receptor engagement (anti-IgM) with or without IL-21. IL-21 mediated STAT3 activation was greater on CD27(-) than CD27(+) B-cells depending on the stimulus. IL-21 alone induced STAT3 phosphorylation (pSTAT3) only on CD27(-) B-cells and IL-21 induced higher pSTAT3 levels on CD27(-) than CD27(+) B-cells after anti-IgM or anti-CD40 activation. CVID CD27(+) B-cells showed selective STAT3 hyperphosphorylation after activation with anti-IgM or anti-CD40 alone and anti-IgM, anti-CD40 or ODN combined with IL-21. Increased STAT3 activation during immune responses could result in B-cell differentiation defects in CVID.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.